<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>FLUCONAZOLE- fluconazole powder, for suspension </strong><br>Teva Pharmaceuticals USA Inc<br></p></div>
<h1>Fluconazole for Oral Suspension</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0c6b4bb2-00a8-4634-8ef7-dcfb03c76aeb"></a><a name="section-1"></a><p></p>
<p class="First"><span class="Bold">Rx only</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_214ec71c-2b3a-465c-917a-8eed6cef969c"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Fluconazole, the first of a new subclass of synthetic triazole antifungal agents, is available for oral administration as a powder for oral suspension. </p>
<p>Fluconazole USP is designated chemically as 2,4-difluoro-α,α<span class="Sup">1</span>-bis(1H-1,2,4-triazol-1-ylmethyl) benzyl alcohol with the following structural formula:</p>
<div class="Figure"><img alt="Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=29bd0efa-fb16-4e69-bb96-8f6bcf80b9f7&amp;name=54a6695b-4502-4454-b56e-653ecd0f3233-01.jpg"></div>
<p>C<span class="Sub">13</span>H<span class="Sub">12</span>F<span class="Sub">2</span>N<span class="Sub">6</span>O                                                                                       M.W. 306.3</p>
<p>Fluconazole USP is a white crystalline solid which is slightly soluble in water and saline.</p>
<p>Fluconazole for Oral Suspension contains 350 mg or 1400 mg of fluconazole USP and the following inactive ingredients: citric acid, colloidal silicon dioxide, dl-alpha-Tocopherol, maltodextrin, natural and artificial flavors, sodium benzoate, sodium citrate, sucrose, titanium dioxide and xanthum gum. After reconstitution with 26 mL or 24 mL of distilled water or Purified Water (USP), each mL of reconstituted suspension contains 10 mg or 40 mg of fluconazole.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_2ca21e6e-e252-4c47-9f38-734e6eeba062"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4e78b86c-fa09-47d1-8466-f7e84b5a099b"></a><a name="section-3.1"></a><p></p>
<h2>Pharmacokinetics and Metabolism</h2>
<p class="First">The pharmacokinetic properties of fluconazole are similar following administration by the intravenous or oral routes. In normal volunteers, the bioavailability of orally administered fluconazole is over 90% compared with intravenous administration. Bioequivalence was established between the 100 mg tablet and both suspension strengths when administered as a single 200 mg dose.</p>
<p>Peak plasma concentrations (C<span class="Sub">max</span>) in fasted normal volunteers occur between 1 and 2 hours with a terminal plasma elimination half-life of approximately 30 hours (range: 20 to 50 hours) after oral administration.</p>
<p>In fasted normal volunteers, administration of a single oral 400 mg dose of fluconazole leads to a mean C<span class="Sub">max</span> of 6.72 mcg/mL (range: 4.12 to 8.08 mcg/mL) and after single oral doses of 50 to 400 mg, fluconazole plasma concentrations and AUC (area under the plasma concentration-time curve) are dose proportional.</p>
<p>The C<span class="Sub">max </span>and AUC data from a food-effect study involving administration of fluconazole tablets to healthy volunteers under fasting conditions and with a high-fat meal indicated that exposure to the drug is not affected by food. Therefore, fluconazole may be taken without regard to meals (see <span class="Bold">DOSAGE AND ADMINISTRATION</span>).</p>
<p>Steady-state concentrations are reached within 5 to 10 days following oral doses of 50 to 400 mg given once daily. Administration of a loading dose (on day 1) of twice the usual daily dose results in plasma concentrations close to steady-state by the second day. The apparent volume of distribution of fluconazole approximates that of total body water. Plasma protein binding is low (11 to 12%). Following either single- or multiple-oral doses for up to 14 days, fluconazole penetrates into all body fluids studied (see table below). In normal volunteers, saliva concentrations of fluconazole were equal to or slightly greater than plasma concentrations regardless of dose, route, or duration of dosing.</p>
<a name="id_67d45561-befc-439d-80f5-9dc4c2f052f1"></a><table border="single" width="443.000">
<col width="49.7%">
<col width="50.3%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="Bold">Tissue or Fluid</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">Ratio of Fluconazole Tissue (Fluid)/Plasma Concentration*</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"> Cerebrospinal fluid<span class="Sup">†</span>
</td>
<td class="Botrule Rrule" align="center" valign="top"> 0.5 to 0.9 </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"> Saliva </td>
<td class="Botrule Rrule" align="center" valign="top"> 1 </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"> <span class="product-label-link" type="condition" conceptid="4102774" conceptname="Productive cough">Sputum</span> </td>
<td class="Botrule Rrule" align="center" valign="top"> 1 </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"> <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> fluid </td>
<td class="Botrule Rrule" align="center" valign="top"> 1 </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"> Urine </td>
<td class="Botrule Rrule" align="center" valign="top"> 10 </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"> Normal skin </td>
<td class="Botrule Rrule" align="center" valign="top"> 10 </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"> Nails </td>
<td class="Botrule Rrule" align="center" valign="top"> 1 </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"> <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> skin </td>
<td class="Botrule Rrule" align="center" valign="top"> 2 </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"> Vaginal tissue </td>
<td class="Botrule Rrule" align="center" valign="top"> 1 </td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top"> Vaginal fluid </td>
<td class="Botrule Rrule" align="center" valign="top"> 0.4 to 0.7 </td>
</tr>
</tbody>
</table>
<p><span class="Bold">*</span> Relative to concurrent concentrations in plasma in subjects with normal renal function.</p>
<p><span class="Sup">†</span> Independent of degree of meningeal <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>.</p>
<p>In normal volunteers, fluconazole is cleared primarily by renal excretion, with approximately 80% of the administered dose appearing in the urine as unchanged drug. About 11% of the dose is excreted in the urine as metabolites.</p>
<p>The pharmacokinetics of fluconazole are markedly affected by reduction in renal function. There is an inverse relationship between the elimination half-life and creatinine clearance. The dose of fluconazole may need to be reduced in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> (see <span class="Bold">DOSAGE AND ADMINISTRATION</span>). A 3 hour hemodialysis session decreases plasma concentrations by approximately 50%.</p>
<p>In normal volunteers, fluconazole administration (doses ranging from 200 mg to 400 mg once daily for up to 14 days) was associated with small and inconsistent effects on testosterone concentrations, endogenous corticosteroid concentrations, and the ACTH-stimulated cortisol response.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_539a4a46-6eef-43fa-8784-77441b72ee96"></a><a name="section-3.2"></a><p></p>
<h2>Pharmacokinetics in Children</h2>
<p class="First">In children, the following pharmacokinetic data {Mean(%cv)} have been reported:</p>
<a name="id_631ce6ac-1b71-4501-a06b-218164e5ef9e"></a><table border="single" width="437.000">
<col width="14.9%">
<col width="16.0%">
<col width="17.6%">
<col width="15.8%">
<col width="16.9%">
<col width="18.8%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">
<p class="First">Age</p>Studied </td>
<td class="Botrule Rrule" align="left" valign="middle">
<p class="First"> Dose</p> (mg/kg) </td>
<td class="Botrule Rrule" align="left" valign="middle">
<p class="First"> Clearance</p> (mL/min/kg) </td>
<td class="Botrule Rrule" align="left" valign="middle">
<p class="First"> Half-life</p> (Hours) </td>
<td class="Botrule Rrule" align="left" valign="middle">
<p class="First"> C<span class="Sub">max</span></p> (mcg/mL) </td>
<td class="Botrule Rrule" align="left" valign="middle">
<p class="First"> Vd<span class="Sub">ss</span></p> (L/kg) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">
<p class="First">  </p>9 Months to 13 years </td>
<td class="Botrule Rrule" align="left" valign="middle">
<p class="First"> Single-Oral</p> 2 mg/kg </td>
<td class="Botrule Rrule" align="left" valign="middle">
<p class="First"> 0.40 (38%)</p> n = 14 </td>
<td class="Botrule Rrule" align="left" valign="middle">
<p class="First"> 25</p>   </td>
<td class="Botrule Rrule" align="left" valign="middle">
<p class="First"> 2.9 (22%)</p> n = 16 </td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">  </p>–</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">
<p class="First">  </p>9 Months to 13 years </td>
<td class="Botrule Rrule" align="left" valign="middle">
<p class="First"> Single-Oral</p> 8 mg/kg </td>
<td class="Botrule Rrule" align="left" valign="middle">
<p class="First"> 0.51 (60%)</p> n = 15 </td>
<td class="Botrule Rrule" align="left" valign="middle">
<p class="First"> 19.5</p>   </td>
<td class="Botrule Rrule" align="left" valign="middle">
<p class="First"> 9.8 (20%)</p> n = 15 </td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">  </p>–</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">
<p class="First">  </p>5 to 15 years </td>
<td class="Botrule Rrule" align="left" valign="middle">
<p class="First"> Multiple IV</p> 2 mg/kg </td>
<td class="Botrule Rrule" align="left" valign="middle">
<p class="First"> 0.49 (40%)</p> n = 4 </td>
<td class="Botrule Rrule" align="left" valign="middle">
<p class="First"> 17.4</p>   </td>
<td class="Botrule Rrule" align="left" valign="middle">
<p class="First"> 5.5 (25%)</p> n = 5 </td>
<td class="Botrule Rrule" align="left" valign="middle">
<p class="First">0.722 (36%) </p>n = 4 </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">
<p class="First">  </p>5 to 15 years </td>
<td class="Botrule Rrule" align="left" valign="middle">
<p class="First"> Multiple IV</p> 4 mg/kg </td>
<td class="Botrule Rrule" align="left" valign="middle">
<p class="First"> 0.59 (64%)</p> n = 5 </td>
<td class="Botrule Rrule" align="left" valign="middle"> 15.2 </td>
<td class="Botrule Rrule" align="left" valign="middle">
<p class="First"> 11.4 (44%)</p> n = 6 </td>
<td class="Botrule Rrule" align="left" valign="middle">
<p class="First"> 0.729 (33%)</p> n = 5 </td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="middle">
<p class="First">  </p>5 to 15 years </td>
<td class="Rrule" align="left" valign="middle">
<p class="First"> Multiple IV</p> 8 mg/kg </td>
<td class="Rrule" align="left" valign="middle">
<p class="First"> 0.66 (31%)</p> n = 7 </td>
<td class="Rrule" align="left" valign="middle"> 17.6 </td>
<td class="Rrule" align="left" valign="middle">
<p class="First"> 14.1 (22%)</p> n = 8 </td>
<td class="Botrule Rrule" align="left" valign="middle">
<p class="First"> 1.069 (37%)</p> n = 7 </td>
</tr>
</tbody>
</table>
<p>Clearance corrected for body weight was not affected by age in these studies. Mean body clearance in adults is reported to be 0.23 (17%) mL/min/kg.</p>
<p>In premature newborns (gestational age 26 to 29 weeks), the mean (%cv) clearance within 36 hours of birth was 0.180 (35%, n = 7) mL/min/kg, which increased with time to a mean of 0.218 (31%, n = 9) mL/min/kg six days later and 0.333 (56%, n = 4) mL/min/kg 12 days later. Similarly, the half-life was 73.6 hours, which decreased with time to a mean of 53.2 hours six days later and 46.6 hours 12 days later.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_925da4c1-a04b-4a74-aa9c-c39d3ab609e2"></a><a name="section-3.3"></a><p></p>
<h2>Pharmacokinetics in Elderly</h2>
<p class="First">A pharmacokinetic study was conducted in 22 subjects, 65 years of age or older receiving a single 50 mg oral dose of fluconazole. Ten of these patients were concomitantly receiving diuretics. The C<span class="Sub">max</span> was 1.54 mcg/mL and occurred at 1.3 hours post dose. The mean AUC was 76.4 ± 20.3 mcg·h/mL, and the mean terminal half-life was 46.2 hours. These pharmacokinetic parameter values are higher than analogous values reported for normal young male volunteers. Coadministration of diuretics did not significantly alter AUC or C<span class="Sub">max</span>. In addition, creatinine clearance (74 mL/min), the percent of drug recovered unchanged in urine (0 to 24 hr, 22%), and the fluconazole renal clearance estimates (0.124 mL/min/kg) for the elderly were generally lower than those of younger volunteers. Thus, the alteration of fluconazole disposition in the elderly appears to be related to reduced renal function characteristic of this group. A plot of each subject’s terminal elimination half-life versus creatinine clearance compared with the predicted half-life – creatinine clearance curve derived from normal subjects and subjects with varying degrees of <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> indicated that 21 of 22 subjects fell within the 95% confidence limit of the predicted half-life – creatinine clearance curves. These results are consistent with the hypothesis that higher values for the pharmacokinetic parameters observed in the elderly subjects compared with normal young male volunteers are due to the decreased kidney function that is expected in the elderly.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f0ddc94e-c711-4149-a4f2-e821d0692261"></a><a name="section-3.4"></a><p></p>
<h2>Drug Interaction Studies</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_65c50507-676a-46ef-b18d-5427b3960d86"></a><a name="section-3.4.1"></a><p></p>
<h3>Oral Contraceptives</h3>
<p class="First">Oral contraceptives were administered as a single dose both before and after the oral administration of fluconazole 50 mg once daily for 10 days in 10 healthy women. There was no significant difference in ethinyl estradiol or levonorgestrel AUC after the administration of 50 mg of fluconazole. The mean increase in ethinyl estradiol AUC was 6% (range: -47 to 108%) and levonorgestrel AUC increased 17% (range: -33 to 141%).</p>
<p>In a second study, twenty-five normal females received daily doses of both 200 mg fluconazole tablets or placebo for two, ten day periods. The treatment cycles were one month apart with all subjects receiving fluconazole during one cycle and placebo during the other. The order of study treatment was random. Single doses of an oral contraceptive tablet containing levonorgestrel and ethinyl estradiol were administered on the final treatment day (day 10) of both cycles. Following administration of 200 mg of fluconazole, the mean percentage increase of AUC for levonorgestrel compared to placebo was 25% (range: -12 to 82%) and the mean percentage increase for ethinyl estradiol compared to placebo was 38% (range: -11 to 101%). Both of these increases were statistically significantly different from placebo.</p>
<p>A third study evaluated the potential interaction of once weekly dosing of fluconazole 300 mg to 21 normal females taking an oral contraceptive containing ethinyl estradiol and norethindrone. In this placebo-controlled, double-blind, randomized, two-way crossover study carried out over three cycles of oral contraceptive treatment, fluconazole dosing resulted in small increases in the mean AUCs of ethinyl estradiol and norethindrone compared to similar placebo dosing. The mean AUCs of ethinyl estradiol and norethindrone increased by 24% (95% CI range: 18 to 31%) and 13% (95% CI range: 8 to 18%), respectively relative to placebo. Fluconazole treatment did not cause a decrease in the ethinyl estradiol AUC of any individual subject in this study compared to placebo dosing. The individual AUC values of norethindrone decreased very slightly (&lt; 5%) in 3 of the 21 subjects after fluconazole treatment.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_66cde945-0561-4689-a1c0-b68e71ce6d90"></a><a name="section-3.4.2"></a><p></p>
<h3>Cimetidine</h3>
<p class="First">Fluconazole 100 mg was administered as a single oral dose alone and two hours after a single dose of cimetidine 400 mg to six healthy male volunteers. After the administration of cimetidine, there was a significant decrease in fluconazole AUC and C<span class="Sub">max</span>. There was a mean ± SD decrease in fluconazole AUC of 13% ± 11% (range: -3.4 to -31%) and C<span class="Sub">max</span> decreased 19% ± 14% (range: -5 to -40%). However, the administration of cimetidine 600 mg to 900 mg intravenously over a four hour period (from one hour before to 3 hours after a single oral dose of fluconazole 200 mg) did not affect the bioavailability or pharmacokinetics of fluconazole in 24 healthy male volunteers.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_14f91b32-f905-467b-86c1-3ea13f0d56b6"></a><a name="section-3.4.3"></a><p></p>
<h3>Antacid</h3>
<p class="First">Administration of calcium carbonate and magnesium carbonate (20 mL) to 14 normal male volunteers immediately prior to a single dose of fluconazole 100 mg had no effect on the absorption or elimination of fluconazole.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_46e0fe0f-62e7-4650-858d-15e1c100ab3f"></a><a name="section-3.4.4"></a><p></p>
<h3>Hydrochlorothiazide</h3>
<p class="First">Concomitant oral administration of 100 mg fluconazole and 50 mg hydrochlorothiazide for 10 days in 13 normal volunteers resulted in a significant increase in fluconazole AUC and C<span class="Sub">max </span>compared to fluconazole given alone. There was a mean ± SD increase in fluconazole AUC and C<span class="Sub">max</span> of 45% ± 31% (range: 19 to 114%) and 43% ± 31% (range: 19 to 122%), respectively. These changes are attributed to a mean ± SD reduction in renal clearance of 30% ± 12% (range: -10 to -50%).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9a3be4ee-1215-4eb8-9b0a-a5a1c991c266"></a><a name="section-3.4.5"></a><p></p>
<h3>Rifampin</h3>
<p class="First">Administration of a single oral 200 mg dose of fluconazole after 15 days of rifampin administered as 600 mg daily in eight healthy male volunteers resulted in a significant decrease in fluconazole AUC and a significant increase in apparent oral clearance of fluconazole. There was a mean ± SD reduction in fluconazole AUC of 23% ± 9% (range: -13 to -42%). Apparent oral clearance of fluconazole increased 32% ± 17% (range: 16 to 72%). Fluconazole half-life decreased from 33.4 ± 4.4 hours to 26.8 ± 3.9 hours (see <span class="Bold">PRECAUTIONS</span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_854b6af5-8b3d-4936-8fc2-1fb8d7123355"></a><a name="section-3.4.6"></a><p></p>
<h3>Warfarin</h3>
<p class="First">There was a significant increase in <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time response (area under the <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time-time curve) following a single dose of warfarin (15 mg) administered to 13 normal male volunteers following oral fluconazole 200 mg administered daily for 14 days as compared to the administration of warfarin alone. There was a mean ± SD increase in the <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time response (area under the <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time-time curve) of 7% ± 4% (range: -2 to 13%) (see <span class="Bold">PRECAUTIONS</span>). Mean is based on data from 12 subjects as one of 13 subjects experienced a 2 fold increase in his <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time response.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d102122d-2eaf-4745-8826-bec5fed1ade0"></a><a name="section-3.4.7"></a><p></p>
<h3>Phenytoin</h3>
<p class="First">Phenytoin AUC was determined after 4 days of phenytoin dosing (200 mg daily, orally for 3 days followed by 250 mg intravenously for one dose) both with and without the administration of fluconazole (oral fluconazole 200 mg daily for 16 days) in 10 normal male volunteers. There was a significant increase in phenytoin AUC. The mean ± SD increase in phenytoin AUC was 88% ± 68% (range: 16 to 247%). The absolute magnitude of this interaction is unknown because of the intrinsically nonlinear disposition of phenytoin (see <span class="Bold">PRECAUTIONS</span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_64f9dfda-1983-47fe-8520-fad1fe8673bc"></a><a name="section-3.4.8"></a><p></p>
<h3>Cyclosporine</h3>
<p class="First">Cyclosporine AUC and C<span class="Sub">max</span> were determined before and after the administration of fluconazole 200 mg daily for 14 days in eight renal transplant patients who had been on cyclosporine therapy for at least 6 months and on a stable cyclosporine dose for at least 6 weeks. There was a significant increase in cyclosporine AUC, C<span class="Sub">max</span>, C<span class="Sub">min</span> (24 hour concentration), and a significant reduction in apparent oral clearance following the administration of fluconazole. The mean ± SD increase in AUC was 92% ± 43% (range: 18 to 147%). The C<span class="Sub">max</span> increased 60% ± 48% (range: -5 to 133%). The C<span class="Sub">min</span> increased 157% ± 96% (range: 33 to 360%). The apparent oral clearance decreased 45% ± 15% (range: -15 to -60%) (see <span class="Bold">PRECAUTIONS</span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_39090d38-b416-4654-9af3-52c7d639c9a4"></a><a name="section-3.4.9"></a><p></p>
<h3>Zidovudine</h3>
<p class="First">Plasma zidovudine concentrations were determined on two occasions (before and following fluconazole 200 mg daily for 15 days) in 13 volunteers with AIDS or ARC who were on a stable zidovudine dose for at least two weeks. There was a significant increase in zidovudine AUC following the administration of fluconazole. The mean ± SD increase in AUC was 20% ± 32% (range: -27 to 104%). The metabolite, GZDV, to parent drug ratio significantly decreased after the administration of fluconazole, from 7.6 ± 3.6 to 5.7 ± 2.2.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_82a84e7d-4108-4567-9d83-67c79e7cb810"></a><a name="section-3.4.10"></a><p></p>
<h3>Theophylline</h3>
<p class="First">The pharmacokinetics of theophylline were determined from a single intravenous dose of aminophylline (6 mg/kg) before and after the oral administration of fluconazole 200 mg daily for 14 days in 16 normal male volunteers. There were significant increases in theophylline AUC, C<span class="Sub">max</span>, and half-life with a corresponding decrease in clearance. The mean ± SD theophylline AUC increased 21% ± 16% (range: -5 to 48%). The C<span class="Sub">max</span> increased 13% ± 17% (range: -13 to 40%). Theophylline clearance decreased 16% ± 11% (range: -32 to 5%). The half-life of theophylline increased from 6.6 ± 1.7 hours to 7.9 ± 1.5 hours (see <span class="Bold">PRECAUTIONS</span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ff78f87f-8111-4c2e-82c9-ed9e96143a9b"></a><a name="section-3.4.11"></a><p></p>
<h3>Terfenadine</h3>
<p class="First">Six healthy volunteers received terfenadine 60 mg BID for 15 days. Fluconazole 200 mg was administered daily from days 9 through 15. Fluconazole did not affect terfenadine plasma concentrations. Terfenadine acid metabolite AUC increased 36% ± 36% (range: 7 to 102%) from day 8 to day 15 with the concomitant administration of fluconazole. There was no change in cardiac repolarization as measured by Holter QTc intervals. Another study at a 400 mg and 800 mg daily dose of fluconazole demonstrated that fluconazole taken in doses of 400 mg per day or greater significantly increases plasma levels of terfenadine when taken concomitantly (see <span class="Bold">CONTRAINDICATIONS </span>and <span class="Bold">PRECAUTIONS</span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3b072e04-bb15-4e8e-8b4a-29bdef040d3e"></a><a name="section-3.4.12"></a><p></p>
<h3>Oral Hypoglycemics</h3>
<p class="First">The effects of fluconazole on the pharmacokinetics of the sulfonylurea oral hypoglycemic agents tolbutamide, glipizide, and glyburide were evaluated in three placebo-controlled studies in normal volunteers. All subjects received the sulfonylurea alone as a single dose and again as a single dose following the administration of fluconazole 100 mg daily for 7 days. In these three studies, 22/46 (47.8%) of fluconazole treated patients and 9/22 (40.1%) of placebo treated patients experienced symptoms consistent with <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> (see <span class="Bold">PRECAUTIONS</span>).</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c62859a8-f492-48b4-8486-27ac48d01e8f"></a><a name="section-3.4.12.1"></a><p></p>
<h4>Tolbutamide</h4>
<p class="First">In 13 normal male volunteers, there was significant increase in tolbutamide (500 mg single dose) AUC and C<span class="Sub">max</span> following the administration of fluconazole. There was a mean ± SD increase in tolbutamide AUC of 26% ± 9% (range: 12 to 39%). Tolbutamide C<span class="Sub">max</span> increased 11% ± 9% (range: -6 to 27%) (see <span class="Bold">PRECAUTIONS</span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0e2d32a9-82e7-447d-ab47-cbf978452706"></a><a name="section-3.4.12.2"></a><p></p>
<h4>Glipizide</h4>
<p class="First">The AUC and C<span class="Sub">max</span> of glipizide (2.5 mg single dose) were significantly increased following the administration of fluconazole in 13 normal male volunteers. There was a mean ± SD increase in AUC of 49% ± 13% (range: 27 to 73%) and an increase in C<span class="Sub">max</span> of 19% ± 23% (range: -11 to 79%) (see <span class="Bold">PRECAUTIONS</span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8a9e8e64-03f6-4245-8fc8-9055b4235cc0"></a><a name="section-3.4.12.3"></a><p></p>
<h4>Glyburide</h4>
<p class="First">The AUC and C<span class="Sub">max </span>of glyburide (5 mg single dose) were significantly increased following the administration of fluconazole in 20 normal male volunteers. There was a mean ± SD increase in AUC of 44% ± 29% (range: -13 to 115%) and C<span class="Sub">max</span> increased 19% ± 19% (range: -23 to 62%). Five subjects required oral glucose following the ingestion of glyburide after 7 days of fluconazole administration (see <span class="Bold">PRECAUTIONS</span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6ee91498-1631-4366-acdd-a5eb75014818"></a><a name="section-3.4.13"></a><p></p>
<h3>Rifabutin</h3>
<p class="First">There have been published reports that an interaction exists when fluconazole is administered concomitantly with rifabutin, leading to increased serum levels of rifabutin (see <span class="Bold">PRECAUTIONS</span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_97c69ea4-049a-47d2-9cbd-cea4899bf47d"></a><a name="section-3.4.14"></a><p></p>
<h3>Tacrolimus</h3>
<p class="First">There have been published reports that an interaction exists when fluconazole is administered concomitantly with tacrolimus, leading to increased serum levels of tacrolimus (see <span class="Bold">PRECAUTIONS</span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_88e30583-3b80-4cad-8eb3-983418937287"></a><a name="section-3.4.15"></a><p></p>
<h3>Cisapride</h3>
<p class="First">A placebo-controlled, randomized, multiple-dose study examined the potential interaction of fluconazole with cisapride. Two groups of 10 normal subjects were administered fluconazole 200 mg daily or placebo. Cisapride 20 mg four times daily was started after 7 days of fluconazole or placebo dosing. Following a single dose of fluconazole, there was a 101% increase in the cisapride AUC and a 91% increase in the cisapride C<span class="Sub">max</span>. Following multiple doses of fluconazole, there was a 192% increase in the cisapride AUC and a 154% increase in the cisapride C<span class="Sub">max</span>. Fluconazole significantly increased the QTc interval in subjects receiving cisapride 20 mg four times daily for 5 days (see <span class="Bold">CONTRAINDICATIONS </span>and <span class="Bold">PRECAUTIONS</span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e07538c5-103e-4e0a-8bea-b2b67a8982b4"></a><a name="section-3.4.16"></a><p></p>
<h3>Midazolam</h3>
<p class="First">The effect of fluconazole on the pharmacokinetics and pharmacodynamics of midazolam was examined in a randomized, crossover study in 12 volunteers. In the study, subjects ingested placebo or 400 mg fluconazole on Day 1 followed by 200 mg daily from Day 2 to Day 6. In addition, a 7.5 mg dose of midazolam was orally ingested on the first day, 0.05 mg/kg was administered intravenously on the fourth day, and 7.5 mg orally on the sixth day. Fluconazole reduced the clearance of IV midazolam by 51%. On the first day of dosing, fluconazole increased the midazolam AUC and C<span class="Sub">max</span> by 259% and 150%, respectively. On the sixth day of dosing, fluconazole increased the midazolam AUC and C<span class="Sub">max</span> by 259% and 74%, respectively. The psychomotor effects of midazolam were significantly increased after oral administration of midazolam but not significantly affected following intravenous midazolam.</p>
<p>A second randomized, double-dummy, placebo-controlled, crossover study in three phases was performed to determine the effect of route of administration of fluconazole on the interaction between fluconazole and midazolam. In each phase the subjects were given oral fluconazole 400 mg and intravenous saline; oral placebo and intravenous fluconazole 400 mg; and oral placebo and IV saline. An oral dose of 7.5 mg of midazolam was ingested after fluconazole/placebo. The AUC and C<span class="Sub">max</span> of midazolam were significantly higher after oral than IV administration of fluconazole. Oral fluconazole increased the midazolam AUC and C<span class="Sub">max </span>by 272% and 129%, respectively. IV fluconazole increased the midazolam AUC and C<span class="Sub">max</span> by 244% and 79%, respectively. Both oral and IV fluconazole increased the pharmacodynamic effects of midazolam (see <span class="Bold">PRECAUTIONS</span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5e0812e1-a2bc-4e54-965f-6afd7a0e57c5"></a><a name="section-3.4.17"></a><p></p>
<h3>Azithromycin</h3>
<p class="First">An open-label, randomized, three-way crossover study in 18 healthy subjects assessed the effect of a single 800 mg oral dose of fluconazole on the pharmacokinetics of a single 1200 mg oral dose of azithromycin as well as the effects of azithromycin on the pharmacokinetics of fluconazole. There was no significant <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interaction</span> between fluconazole and azithromycin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_21ff91ef-2caf-4050-b0f2-13f749d6bfce"></a><a name="section-3.4.18"></a><p></p>
<h3>Voriconazole</h3>
<p class="First">Voriconazole is a substrate for both CYP2C9 and CYP3A4 isoenzymes. Concurrent administration of oral voriconazole (400 mg Q12h for 1 day, then 200 mg Q12h for 2.5 days) and oral fluconazole (400 mg on day 1, then 200 mg Q24h for 4 days) to 6 healthy male subjects resulted in an increase in C<span class="Sub">max</span> and AUCτ of voriconazole by an average of 57% (90% CI: 20%, 107%) and 79% (90% CI: 40%, 128%), respectively. In a follow-on clinical study involving 8 healthy male subjects, reduced dosing and/or frequency of voriconazole and fluconazole did not eliminate or diminish this effect. Concomitant administration of voriconazole and fluconazole at any dose is not recommended. Close monitoring for adverse events related to voriconazole is recommended if voriconazole is used sequentially after fluconazole, especially within 24 h of the last dose of fluconazole (see <span class="Bold">PRECAUTIONS</span>). </p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7312e2bb-6498-4e5c-8fa9-4b3870f6f1e3"></a><a name="section-3.5"></a><p></p>
<h2>Microbiology</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3df6e393-1eb8-4fdc-b1f8-26cc98edf250"></a><a name="section-3.5.1"></a><p></p>
<h3>Mechanism of Action</h3>
<p class="First">Fluconazole is a highly selective inhibitor of fungal cytochrome P-450 dependent enzyme lanosterol 14-α-demethylase. This enzyme functions to convert lanosterol to ergosterol. The subsequent loss of normal sterols correlates with the accumulation of 14-α-methyl sterols in fungi and may be responsible for the fungistatic activity of fluconazole. Mammalian cell demethylation is much less sensitive to fluconazole inhibition.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4778f18e-e3a5-4497-8be2-6eb9bd8bd7a8"></a><a name="section-3.5.2"></a><p></p>
<h3>Activity In Vitro and In Clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></h3>
<p class="First">Fluconazole has been shown to be active against most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following microorganisms <span class="Bold">both <span class="Italics">in vitro </span>and in clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> albicans </span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> glabrata </span>(Many <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> are intermediately susceptible)<span class="Sup">*</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> parapsilosis </span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> tropicalis </span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="440035" conceptname="Cryptococcosis">Cryptococcus neoformans</span> </span></p>
<p><span class="Italics"><span class="Sup">*</span> In a majority of the studies, fluconazole MIC<span class="Sub">90 </span>values against C. glabrata were above the susceptible breakpoint (</span>≥ <span class="Italics">16 mcg/mL). Resistance in <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> glabrata usually includes upregulation of CDR genes resulting in resistance to multiple azoles. For an isolate where the MIC is categorized as intermediate (16 to 32 mcg/mL, see  </span><span class="Bold">Table 1</span><span class="Italics">), the highest dose is recommended (see  </span><span class="Bold">DOSAGE AND ADMINISTRATION</span><span class="Italics">). For resistant isolates alternative therapy is recommended. </span></p>
<p>The following <span class="Italics">in vitro </span>data are available, <span class="Bold">but their clinical significance is unknown. </span></p>
<p>Fluconazole exhibits <span class="Italics">in vitro </span><span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentrations</span> (MIC values) of 8 mcg/mL or less against most (≥ 90%) <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following microorganisms, however, the safety and effectiveness of fluconazole in treating clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to these microorganisms have not been established in adequate and well-controlled trials. </p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> dubliniensis </span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> guilliermondii </span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> kefyr </span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> lusitaniae </span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> krusei </span>should be considered to be resistant to fluconazole. Resistance in <span class="Italics">C. krusei </span>appears to be mediated by reduced sensitivity of the target enzyme to inhibition by the agent. </p>
<p>There have been reports of cases of <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfection</span> with <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> </span>species other than <span class="Italics">C. albicans, </span>which are often inherently not susceptible to fluconazole (e.g., <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> krusei</span>). Such cases may require alternative antifungal therapy. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1595f2b0-cd6c-4893-9bc5-69042cad0e2d"></a><a name="section-3.5.3"></a><p></p>
<h3>Susceptibility Testing Methods </h3>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="440035" conceptname="Cryptococcosis">Cryptococcus neoformans</span> and filamentous fungi</span></p>
<p>No interpretive criteria have been established for <span class="Italics"><span class="product-label-link" type="condition" conceptid="440035" conceptname="Cryptococcosis">Cryptococcus neoformans</span></span> and filamentous fungi.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> species</span></p>
<p>Broth Dilution Techniques – Quantitative methods are used to determine antifungal <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentrations</span> (MICs). These MICs provide estimates of the susceptibility of <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span></span> spp. to antifungal agents. MICs should be determined using a standardized procedure. Standardized procedures are based on a dilution method (broth)<span class="Sup">1</span> with standardized inoculum concentrations of fluconazole powder. The MIC values should be interpreted according to the criteria provided in <span class="Bold">Table 1</span>. </p>
<p>Diffusion Techniques – Qualitative methods that require measurement of zone diameters also provide reproducible estimates of the susceptibility of <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span></span> spp. to an antifungal agent. One such standardized procedure<span class="Sup">2</span> requires the use of standardized inoculum concentrations. This procedure uses paper disks impregnated with 25 mcg of fluconazole to test the susceptibility of yeasts to fluconazole. Disk diffusion interpretive criteria are also provided in <span class="Bold">Table 1</span>. </p>
<p><span class="Bold">Table 1: Susceptibility Interpretive Criteria for Fluconazole</span></p>
<a name="id_9337481d-f714-4a4f-bc72-5a6ca55090a3"></a><table border="single" width="485.000">
<col width="14.8%">
<col width="14.6%">
<col width="14.8%">
<col width="12.4%">
<col width="14.8%">
<col width="14.8%">
<col width="13.6%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">   </td>
<td class="Botrule Rrule" align="center" colspan="3" valign="top">
<p class="First">Broth Dilution at 48 hours</p>(MIC in mcg/mL)</td>
<td class="Botrule Rrule" align="center" colspan="3" valign="top">
<p class="First">Disk Diffusion at 24 hours</p>(Zone Diameters in mm)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">Antifungal agent</td>
<td class="Botrule Rrule" align="center" valign="top">Susceptible (S)</td>
<td class="Botrule Rrule" align="center" valign="top">Intermediate (I)<span class="Sup">**</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">Resistant (R)</td>
<td class="Botrule Rrule" align="center" valign="top">Susceptible (S)</td>
<td class="Botrule Rrule" align="center" valign="top">Intermediate (I)<span class="Sup">**</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">Resistant (R)</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" valign="top">Fluconazole<span class="Sup">*</span>
</td>
<td class="Rrule" align="center" valign="top">≤ 8</td>
<td class="Rrule" align="center" valign="top">16 to 32</td>
<td class="Rrule" align="center" valign="top">≥ 64</td>
<td class="Rrule" align="center" valign="top">≥ 19</td>
<td class="Rrule" align="center" valign="top">15 to 18</td>
<td class="Botrule Rrule" align="center" valign="top">≤ 14</td>
</tr>
</tbody>
</table>
<p><span class="Sup">*</span> Isolates of <span class="Italics">C. krusei </span>are assumed to be intrinsically resistant to fluconazole and their MICs and/or zone diameters should not be interpreted using this scale. </p>
<p><span class="Sup">**</span> The intermediate category is sometimes called Susceptible-Dose Dependent (SDD) and both categories are equivalent for fluconazole. </p>
<p>The susceptible category implies that isolates are inhibited by the usually achievable concentrations of antifungal agent tested when the recommended dosage is used. The intermediate category implies that an <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> due to the isolate may be appropriately treated in body sites where the drugs are physiologically concentrated or when a high dosage of drug is used. The resistant category implies that isolates are not inhibited by the usually achievable concentrations of the agent with normal dosage schedules and clinical efficacy of the agent against the isolate has not been reliably shown in treatment studies. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9e3f1f68-153d-4b5f-a067-3fc87323be33"></a><a name="section-3.5.4"></a><p></p>
<h3>Quality Control </h3>
<p class="First">Standardized susceptibility test procedures require the use of quality control organisms to control the technical aspects of the test procedures. Standardized fluconazole powder and 25 mcg disks should provide the following range of values noted in <span class="Bold">Table 2</span>. NOTE: Quality control microorganisms are specific <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of organisms with intrinsic biological properties relating to resistance mechanisms and their genetic expression within fungi; the specific <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> used for microbiological control are not clinically significant.</p>
<p><span class="Bold">Table 2: Acceptable Quality Control Ranges for Fluconazole to be Used in Validation of Susceptibility Test Results</span></p>
<a name="id_37ec5114-eb0d-4b51-ba2d-6d3ac982f9f7"></a><table border="single" width="473.000">
<col width="27.7%">
<col width="22.8%">
<col width="21.6%">
<col width="27.9%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">QC <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">Strain</span></td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">Macrodilution</p>
<p>(MIC in mcg/mL)</p>@ 48 hours</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">Microdilution</p>
<p>(MIC in mcg/mL)</p>@ 48 hours</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">Disk Diffusion</p>
<p>(Zone Diameter in mm)</p>@ 24 hours</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> parapsilosis </span>ATCC 22019 </td>
<td class="Botrule Rrule" align="center" valign="top"> 2 to 8 </td>
<td class="Botrule Rrule" align="center" valign="top"> 1 to 4 </td>
<td class="Botrule Rrule" align="center" valign="top"> 22 to 33 </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> krusei </span>ATCC 6258 </td>
<td class="Botrule Rrule" align="center" valign="top"> 16 to 64 </td>
<td class="Botrule Rrule" align="center" valign="top"> 16 to 128 </td>
<td class="Botrule Rrule" align="center" valign="top"> ---<span class="Sup">*</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> albicans </span>ATCC 90028 </td>
<td class="Botrule Rrule" align="center" valign="top"> ---<span class="Sup">*</span>
</td>
<td class="Botrule Rrule" align="center" valign="top"> ---<span class="Sup">*</span>
</td>
<td class="Botrule Rrule" align="center" valign="top"> 28 to 39 </td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">
<span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> tropicalis </span>ATCC 750 </td>
<td class="Rrule" align="center" valign="top"> ---<span class="Sup">*</span>
</td>
<td class="Rrule" align="center" valign="top"> ---<span class="Sup">*</span>
</td>
<td class="Botrule Rrule" align="center" valign="top"> 26 to 37 </td>
</tr>
</tbody>
</table>
<p>---<span class="Sup">*</span> Quality control ranges have not been established for this <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span>/antifungal agent combination due to their extensive interlaboratory variation during initial quality control studies. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_15395730-a6ba-4ab4-9be1-fab0a2d4e5d4"></a><a name="section-3.5.5"></a><p></p>
<h3>Activity In Vivo </h3>
<p class="First">Fungistatic activity has also been demonstrated in normal and immunocompromised animal models for systemic and intracranial <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span> due to <span class="Italics"><span class="product-label-link" type="condition" conceptid="440035" conceptname="Cryptococcosis">Cryptococcus neoformans</span> </span>and for systemic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> albicans</span>. </p>
<p>In common with other azole antifungal agents, most fungi show a higher apparent sensitivity to fluconazole <span class="Italics">in vivo </span>than <span class="Italics">in vitro</span>. Fluconazole administered orally and/or intravenously was active in a variety of animal models of <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infection</span> using standard laboratory <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of fungi. Activity has been demonstrated against <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span> caused by <span class="Italics">Aspergillus flavus </span>and <span class="Italics">Aspergillus fumigatus </span>in normal mice. Fluconazole has also been shown to be active in animal models of endemic mycoses, including one model of <span class="Italics">Blastomyces dermatitidis </span>pulmonary <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> in normal mice; one model of <span class="Italics">Coccidioides immitis </span>intracranial <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> in normal mice; and several models of <span class="Italics">Histoplasma capsulatum </span>pulmonary <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> in normal and immunosuppressed mice. The clinical significance of results obtained in these studies is unknown. </p>
<p>Concurrent administration of fluconazole and amphotericin B in infected normal and immunosuppressed mice showed the following results: a small additive antifungal effect in systemic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> with <span class="Italics">C. albicans, </span>no interaction in intracranial <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> with <span class="Italics"><span class="product-label-link" type="condition" conceptid="440035" conceptname="Cryptococcosis">Cryptococcus neoformans</span>, </span>and antagonism of the two drugs in systemic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> with <span class="Italics">A. fumigatus</span>. The clinical significance of results obtained in these studies is unknown. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_18739091-eb7d-4c5a-87e1-6fa2d6e1e082"></a><a name="section-3.5.6"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="4150981" conceptname="Drug resistance">Drug Resistance</span></h3>
<p class="First">Fluconazole resistance may arise from a modification in the quality or quantity of the target enzyme (lanosterol 14-α-demethylase), reduced access to the drug target, or some combination of these mechanisms. </p>
<p>Point mutations in the gene (<span class="Italics">ERG11</span>) encoding for the target enzyme lead to an altered target with decreased affinity for azoles. Overexpression of <span class="Italics">ERG11 </span>results in the production of high concentrations of the target enzyme, creating the need for higher intracellular drug concentrations to inhibit all of the enzyme molecules in the cell.</p>
<p>The second major mechanism of <span class="product-label-link" type="condition" conceptid="4150981" conceptname="Drug resistance">drug resistance</span> involves active efflux of fluconazole out of the cell through the activation of two types of multidrug efflux transporters; the major facilitators (encoded by <span class="Italics">MDR </span>genes) and those of the ATP-binding cassette superfamily (encoded by <span class="Italics">CDR </span>genes). Upregulation of the <span class="Italics">MDR </span>gene leads to fluconazole resistance, whereas, upregulation of <span class="Italics">CDR </span>genes may lead to resistance to multiple azoles. </p>
<p>Resistance in <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> glabrata </span>usually includes upregulation of <span class="Italics">CDR</span> genes resulting in resistance to multiple azoles. For an isolate where the MIC is categorized as Intermediate (16 to 32 mcg/mL), the highest fluconazole dose is recommended. </p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> krusei </span>should be considered to be resistant to fluconazole. Resistance in <span class="Italics">C. krusei </span>appears to be mediated by reduced sensitivity of the target enzyme to inhibition by the agent.</p>
<p>There have been reports of cases of <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfection</span> with <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span></span> species other than <span class="Italics">C. albicans</span>, which are often inherently not susceptible to fluconazole (e.g., <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> krusei</span>). Such cases may require alternative antifungal therapy.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_0956c7df-a4d6-4eac-9dfe-67c84d49a1a9"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Fluconazole for Oral Suspension is indicated for the treatment of:</p>
<ol>
<li>Oropharyngeal and <span class="product-label-link" type="condition" conceptid="28974" conceptname="Candidiasis of the esophagus">esophageal candidiasis</span>.  In open noncomparative studies of relatively small numbers of patients, fluconazole was also effective for the treatment of <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span></span> <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span>, <span class="product-label-link" type="condition" conceptid="196152" conceptname="Peritonitis">peritonitis</span>, and systemic <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span></span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> including <span class="product-label-link" type="condition" conceptid="438077" conceptname="Invasive candidiasis">candidemia</span>, <span class="product-label-link" type="condition" conceptid="438077" conceptname="Invasive candidiasis">disseminated candidiasis</span>, and <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>.</li>
<li><span class="product-label-link" type="condition" conceptid="432310" conceptname="Cryptococcal meningitis">Cryptococcal meningitis</span>.  Before prescribing fluconazole for AIDS patients with <span class="product-label-link" type="condition" conceptid="432310" conceptname="Cryptococcal meningitis">cryptococcal meningitis</span>, please see <span class="Bold">CLINICAL STUDIES</span> section.  Studies comparing fluconazole to amphotericin B in non-HIV infected patients have not been conducted.</li>
</ol>
<p><span class="Bold">Prophylaxis</span></p>
<p>Fluconazole for Oral Suspension is also indicated to decrease the incidence of <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">candidiasis</span> in patients undergoing bone marrow transplantation who receive cytotoxic chemotherapy and/or radiation therapy.</p>
<p>Specimens for fungal culture and other relevant laboratory studies (serology, histopathology) should be obtained prior to therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d658d435-5fb3-48e5-bbbc-714dc7fe63b6"></a><a name="section-4.1"></a><p></p>
<h2>CLINICAL STUDIES</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6a37b84f-57a5-418d-8550-cc1007b919cb"></a><a name="section-4.1.1"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="432310" conceptname="Cryptococcal meningitis">Cryptococcal Meningitis</span></h3>
<p class="First">In a multicenter study comparing fluconazole (200 mg/day) to amphotericin B (0.3 mg/kg/day) for treatment of <span class="product-label-link" type="condition" conceptid="432310" conceptname="Cryptococcal meningitis">cryptococcal meningitis</span> in patients with AIDS, a multivariate analysis revealed three pretreatment factors that predicted <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> during the course of therapy: abnormal mental status, cerebrospinal fluid cryptococcal antigen titer greater than 1:1024, and cerebrospinal fluid white blood cell count of less than 20 cells/mm<span class="Sup">3</span>. Mortality among high risk patients was 33% and 40% for amphotericin B and fluconazole patients, respectively (p = 0.58), with overall <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> 14% (9 of 63 subjects) and 18% (24 of 131 subjects) for the 2 arms of the study (p = 0.48). Optimal doses and regimens for patients with acute <span class="product-label-link" type="condition" conceptid="432310" conceptname="Cryptococcal meningitis">cryptococcal meningitis</span> and at high risk for treatment failure remain to be determined. (Saag, <span class="Italics">et al</span>. N Engl J Med 1992; 326:83-9.)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_00d57c9e-bfe3-4c04-8871-cbcdbfef6e64"></a><a name="section-4.1.2"></a><p></p>
<h3>Pediatric Studies</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9f695063-87c6-452e-8e30-ea25f3875b3f"></a><a name="section-4.1.2.1"></a><p></p>
<h4><span class="product-label-link" type="condition" conceptid="4080451" conceptname="Pharyngeal candidiasis">Oropharyngeal Candidiasis</span></h4>
<p class="First">An open-label, comparative study of the efficacy and safety of fluconazole (2 to 3 mg/kg/day) and oral nystatin (400,000 I.U. 4 times daily) in immunocompromised children with <span class="product-label-link" type="condition" conceptid="4080451" conceptname="Pharyngeal candidiasis">oropharyngeal candidiasis</span> was conducted. Clinical and mycological response rates were higher in the children treated with fluconazole.</p>
<p>Clinical cure at the end of treatment was reported for 86% of fluconazole treated patients compared to 46% of nystatin treated patients. Mycologically, 76% of fluconazole treated patients had the infecting organism eradicated compared to 11% for nystatin treated patients.</p>
<a name="id_ae2da1d3-aa19-459e-9f0a-0c912f2fd175"></a><table border="single" width="330">
<col width="40.3%">
<col width="28.2%">
<col width="31.5%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold"> </span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold"><span class="Underline">Fluconazole</span></span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold"><span class="Underline">Nystatin</span></span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"> Enrolled </td>
<td class="Botrule Rrule" align="center" valign="top"> 96 </td>
<td class="Botrule Rrule" align="center" valign="top"> 90 </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"> Clinical Cure </td>
<td class="Botrule Rrule" align="center" valign="top"> 76/88 (86%) </td>
<td class="Botrule Rrule" align="center" valign="top"> 36/78 (46%) </td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top"> Mycological eradication<span class="Sup">*</span>
</td>
<td class="Rrule" align="center" valign="top"> 55/72 (76%) </td>
<td class="Botrule Rrule" align="center" valign="top"> 6/54 (11%) </td>
</tr>
</tbody>
</table>
<p><span class="Sup">*</span>Subjects without follow-up cultures for any reason were considered nonevaluable for mycological response. </p>
<p>The proportion of patients with clinical relapse 2 weeks after the end of treatment was 14% for subjects receiving fluconazole and 16% for subjects receiving nystatin. At 4 weeks after the end of treatment, the percentages of patients with clinical relapse were 22% for fluconazole and 23% for nystatin.</p>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_480471da-08be-457f-ab42-e1e62bea3d19"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Fluconazole for Oral Suspension is contraindicated in patients who have shown <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to fluconazole or to any of its excipients. There is no information regarding cross-<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> between fluconazole and other azole antifungal agents. Caution should be used in prescribing fluconazole to patients with <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to other azoles. Coadministration of terfenadine is contraindicated in patients receiving fluconazole at multiple doses of 400 mg or higher based upon results of a multiple dose interaction study. Coadministration of other drugs known to prolong the QT interval and which are metabolized via the enzyme CYP3A4 such as cisapride, astemizole, pimozide, and quinidine are contraindicated in patients receiving fluconazole (see <span class="Bold">CLINICAL PHARMACOLOGY, Drug Interaction Studies</span> and <span class="Bold">PRECAUTIONS</span>).</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_448f81fb-5dea-42b1-8444-a3ae7f7c2496"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_26f3fc8d-594e-457e-996b-35c6a9639fad"></a><a name="section-6.1"></a><p></p>
<h2>(1) Hepatic Injury</h2>
<p class="First"><span class="Bold"><span class="Bold">Fluconazole should be administered with caution to patients with liver dysfunction. Fluconazole has been associated with rare cases of serious hepatic toxicity, including fatalities primarily in patients with serious underlying medical conditions. In cases of fluconazole-associated hepatotoxicity, no obvious relationship to total daily dose, duration of therapy, sex, or age of the patient has been observed. Fluconazole hepatotoxicity has usually, but not always, been reversible on discontinuation of therapy.</span> Patients who develop <span class="product-label-link" type="condition" conceptid="438878" conceptname="Liver function tests abnormal">abnormal liver function tests</span> during fluconazole therapy should be monitored for the development of more severe hepatic injury. Fluconazole should be discontinued if clinical signs and symptoms consistent with liver disease develop that may be attributable to fluconazole.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_191c4891-1b10-4324-9728-49b0f754e93c"></a><a name="section-6.2"></a><p></p>
<h2>(2) <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span></h2>
<p class="First">In rare cases, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> has been reported.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_34adea70-1007-406b-a12d-4e20bb30d1f8"></a><a name="section-6.3"></a><p></p>
<h2>(3) Dermatologic</h2>
<p class="First">Patients have rarely developed exfoliative <span class="product-label-link" type="condition" conceptid="140842" conceptname="Changes in skin texture">skin disorders</span> during treatment with fluconazole. In patients with serious underlying diseases (predominantly AIDS and malignancy), these have rarely resulted in a fatal outcome. Patients who develop <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rashes</span> during treatment with fluconazole should be monitored closely and the drug discontinued if lesions progress.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_79017c7a-cb01-4c58-9c24-872fb8da081c"></a><a name="section-6.4"></a><p></p>
<h2>(4) Use in Pregnancy</h2>
<p class="First">There are no adequate and well-controlled studies of fluconazole in pregnant women. Available human data do not suggest an increased risk of congenital anomalies following a single maternal dose of 150 mg. A few published case reports describe a rare pattern of distinct congenital anomalies in infants exposed<span class="Italics"> in utero</span> to high dose maternal fluconazole (400 to 800 mg/day) during most or all of the first trimester. These reported anomalies are similar to those seen in animal studies. If this drug is used during pregnancy, or if the patient becomes pregnant while taking the drug, the patient should be informed of the potential hazard to the fetus (see <span class="Bold">PRECAUTIONS, Pregnancy</span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_771d6bcf-36f0-49f9-9f6d-3f9845c5fbf6"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b5c8886a-bff4-49ba-b5e1-27eb3526e862"></a><a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First">Some azoles, including fluconazole, have been associated with prolongation of the QT interval on the electrocardiogram. During postmarketing surveillance, there have been rare cases of QT prolongation and <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsade de pointes</span> in patients taking fluconazole. Most of these reports involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities and concomitant medications that may have been contributory. </p>
<p>Fluconazole should be administered with caution to patients with these potentially proarrhythmic conditions.</p>
<p>Concomitant use of fluconazole and erythromycin has the potential to increase the risk of cardiotoxicity (prolonged QT interval, <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsade de pointes</span>) and consequently sudden heart <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. This combination should be avoided. </p>
<p>Fluconazole should be administered with caution to patients with renal dysfunction. </p>
<p>Fluconazole is a potent CYP2C9 inhibitor and a moderate CYP3A4 inhibitor. Fluconazole-treated patients who are concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4 should be monitored. </p>
<p>Fluconazole for oral suspension contains sucrose and should not be used in patients with hereditary fructose, glucose/galactose <span class="product-label-link" type="condition" conceptid="194993" conceptname="Intestinal malabsorption">malabsorption</span>, and sucrase-isomaltase deficiency. </p>
<p>When driving vehicles or operating machines, it should be taken into account that occasionally <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> or <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> may occur.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6ff1f9a0-bd26-42c5-bae5-7cd8f805380e"></a><a name="section-7.2"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">(See <span class="Bold">CLINICAL PHARMACOLOGY</span>,<span class="Bold"> Drug Interaction Studies </span>and <span class="Bold">CONTRAINDICATIONS.</span>) Fluconazole is a potent inhibitor of cytochrome P450 (CYP) isoenzyme 2C9 and a moderate inhibitor of CYP3A4. In addition to the observed /documented interactions mentioned below, there is a risk of increased plasma concentration of other compounds metabolized by CYP2C9 and CYP3A4 coadministered with fluconazole. Therefore, caution should be exercised when using these combinations and the patients should be carefully monitored. The enzyme inhibiting effect of fluconazole persists 4 to 5 days after discontinuation of fluconazole treatment due to the long half-life of fluconazole. Clinically or potentially significant drug interactions between fluconazole and the following agents/classes have been observed. These are described in greater detail below:</p>
<p>Oral hypoglycemics</p>
<p>Coumarin-type anticoagulants</p>
<p>Phenytoin</p>
<p>Cyclosporine</p>
<p>Rifampin</p>
<p>Theophylline</p>
<p>Terfenadine</p>
<p>Cisapride</p>
<p>Astemizole</p>
<p>Rifabutin</p>
<p>Voriconazole</p>
<p>Tacrolimus</p>
<p>Short-acting benzodiazepines</p>
<p>Triazolam </p>
<p>Oral Contraceptives </p>
<p>Pimozide </p>
<p>Hydrochlorothiazide </p>
<p>Alfentanil </p>
<p>Amitriptyline, nortriptyline </p>
<p>Amphotericin B </p>
<p>Azithromycin </p>
<p>Carbamazepine </p>
<p>Calcium Channel Blockers </p>
<p>Celecoxib </p>
<p>Cyclophosphamide </p>
<p>Fentanyl </p>
<p>Halofantrine </p>
<p>HMG-CoA reductase inhibitors </p>
<p>Losartan </p>
<p>Methadone </p>
<p>Non-steroidal anti-inflammatory drugs </p>
<p>Prednisone </p>
<p>Saquinavir </p>
<p>Sirolimus </p>
<p>Vinca Alkaloids </p>
<p>Vitamin A </p>
<p>Zidovudine</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3c924692-f5d2-4605-8a7d-73858039eecb"></a><a name="section-7.2.1"></a><p></p>
<h3><span class="Bold">Oral Hypoglycemics</span></h3>
<p class="First">Clinically significant <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> in association with combined fluconazole and glyburide use. Fluconazole reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these agents. When fluconazole is used concomitantly with these or other sulfonylurea oral hypoglycemic agents, blood glucose concentrations should be carefully monitored and the dose of the sulfonylurea should be adjusted as necessary (see <span class="Bold">CLINICAL PHARMACOLOGY</span>, <span class="Bold">Drug Interaction Studies</span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_27bfd331-d8b2-466d-911b-f78263f19cea"></a><a name="section-7.2.2"></a><p></p>
<h3><span class="Bold">Coumarin-Type Anticoagulants</span></h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">Prothrombin</span> time may be increased in patients receiving concomitant fluconazole and coumarin-type anticoagulants. In postmarketing experience, as with other azole antifungals, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> events (<span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span>, <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>, <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span>, <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>, and <span class="product-label-link" type="condition" conceptid="193809" conceptname="Melena due to gastrointestinal hemorrhage">melena</span>) have been reported in association with increases in <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time in patients receiving fluconazole concurrently with warfarin. Careful monitoring of <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time in patients receiving fluconazole and coumarin-type anticoagulants is recommended. Dose adjustment to warfarin may be necessary (see <span class="Bold">CLINICAL PHARMACOLOGY,</span><span class="Bold">Drug Interaction Studies</span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e3edceed-c995-42af-9696-b2a08733b788"></a><a name="section-7.2.3"></a><p></p>
<h3><span class="Bold">Phenytoin</span></h3>
<p class="First">Fluconazole increases the plasma concentrations of phenytoin. Careful monitoring of phenytoin concentrations in patients receiving fluconazole and phenytoin is recommended (see <span class="Bold">CLINICAL PHARMACOLOGY</span>, <span class="Bold">Drug Interaction Studies</span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ac635726-3ccb-49e0-b8c1-fe84ab508e6b"></a><a name="section-7.2.4"></a><p></p>
<h3><span class="Bold">Cyclosporine</span></h3>
<p class="First">Fluconazole may significantly increase cyclosporine levels in renal transplant patients with or without <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Careful monitoring of cyclosporine concentrations and serum creatinine is recommended in patients receiving fluconazole and cyclosporine (see <span class="Bold">CLINICAL PHARMACOLOGY, Drug Interaction Studies</span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e9ad9d71-99f3-47f4-b34f-01fafa1385d8"></a><a name="section-7.2.5"></a><p></p>
<h3><span class="Bold">Rifampin</span></h3>
<p class="First">Rifampin enhances the metabolism of concurrently administered fluconazole. Depending on clinical circumstances, consideration should be given to increasing the dose of fluconazole when it is administered with rifampin (see <span class="Bold">CLINICAL PHARMACOLOGY</span>, <span class="Bold">Drug Interaction Studies</span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e63532d0-63de-4bf8-99f0-161b70deaafd"></a><a name="section-7.2.6"></a><p></p>
<h3><span class="Bold">Theophylline</span></h3>
<p class="First">Fluconazole increases the serum concentrations of theophylline. Careful monitoring of serum theophylline concentrations in patients receiving fluconazole and theophylline is recommended (see <span class="Bold">CLINICAL PHARMACOLOGY</span>, <span class="Bold">Drug Interaction Studies</span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_be1db4a5-13d9-4406-a4ae-528f5a299693"></a><a name="section-7.2.7"></a><p></p>
<h3><span class="Bold">Terfenadine</span></h3>
<p class="First">Because of the occurrence of serious <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac dysrhythmias</span> secondary to prolongation of the QTc interval in patients receiving azole antifungals in conjunction with terfenadine, interaction studies have been performed. One study at a 200 mg daily dose of fluconazole failed to demonstrate a prolongation in QTc interval. Another study at a 400 mg and 800 mg daily dose of fluconazole demonstrated that fluconazole taken in doses of 400 mg per day or greater significantly increases plasma levels of terfenadine when taken concomitantly. The combined use of fluconazole at doses of 400 mg or greater with terfenadine is contraindicated (see <span class="Bold">CONTRAINDICATIONS </span>and <span class="Bold">CLINICAL PHARMACOLOGY, Drug Interaction Studies</span>). The coadministration of fluconazole at doses lower than 400 mg/day with terfenadine should be carefully monitored.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_bb5fc2ff-52d1-41ab-98cf-95fdb1663c3c"></a><a name="section-7.2.8"></a><p></p>
<h3><span class="Bold">Cisapride</span></h3>
<p class="First">There have been reports of cardiac events, including <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsade de pointes</span> in patients to whom fluconazole and cisapride were coadministered. A controlled study found that concomitant fluconazole 200 mg once daily and cisapride 20 mg four times a day yielded a significant increase in cisapride plasma levels and prolongation of QTc interval. The combined use of fluconazole with cisapride is contraindicated (see <span class="Bold">CONTRAINDICATIONS </span>and <span class="Bold">CLINICAL PHARMACOLOGY, Drug Interaction Studies</span>). </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_aa6eff04-c024-4da6-8343-d80ef994c657"></a><a name="section-7.2.9"></a><p></p>
<h3><span class="Bold">Astemizole</span></h3>
<p class="First">Concomitant administration of fluconazole with astemizole may decrease the clearance of astemizole. Resulting increased plasma concentrations of astemizole can lead to QT prolongation and rare occurrences of <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsade de pointes</span>. Coadministration of fluconazole and astemizole is contraindicated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4c10e3e5-d45b-458d-8d3f-8ccb663aa59e"></a><a name="section-7.2.10"></a><p></p>
<h3><span class="Bold">Rifabutin</span></h3>
<p class="First">There have been reports that an interaction exists when fluconazole is administered concomitantly with rifabutin, leading to increased serum levels of rifabutin up to 80%. There have been reports of <span class="product-label-link" type="condition" conceptid="4028363" conceptname="Uveitis">uveitis</span> in patients to whom fluconazole and rifabutin were coadministered. Patients receiving rifabutin and fluconazole concomitantly should be carefully monitored (see <span class="Bold">CLINICAL PHARMACOLOGY, Drug Interaction Studies</span>). </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e54ab2d1-a98d-47de-90b8-3e57c67f0ef0"></a><a name="section-7.2.11"></a><p></p>
<h3><span class="Bold">Voriconazole</span></h3>
<p class="First">Avoid concomitant administration of voriconazole and fluconazole. Monitoring for adverse events and toxicity related to voriconazole is recommended; especially, if voriconazole is started within 24 h after the last dose of fluconazole (see <span class="Bold">CLINICAL PHARMACOLOGY, Drug Interaction Studies</span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7727babf-ce3a-4cf4-8214-77f5b4190580"></a><a name="section-7.2.12"></a><p></p>
<h3><span class="Bold">Tacrolimus</span></h3>
<p class="First">Fluconazole may increase the serum concentrations of orally administered tacrolimus up to 5 times due to inhibition of tacrolimus metabolism through CYP3A4 in the intestines. No significant pharmacokinetic changes have been observed when tacrolimus is given intravenously. Increased tacrolimus levels have been associated with <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span>. Dosage of orally administered tacrolimus should be decreased depending on tacrolimus concentration (see <span class="Bold">CLINICAL PHARMACOLOGY, Drug Interaction Studies</span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f99f9aff-b80c-4e84-9fbf-e3ac78fdc47e"></a><a name="section-7.2.13"></a><p></p>
<h3><span class="Bold">Short-Acting Benzodiazepines</span></h3>
<p class="First">Following oral administration of midazolam, fluconazole resulted in substantial increases in midazolam concentrations and psychomotor effects. This effect on midazolam appears to be more pronounced following oral administration of fluconazole than with fluconazole administered intravenously. If short-acting benzodiazepines, which are metabolized by the cytochrome P450 system, are concomitantly administered with fluconazole, consideration should be given to decreasing the benzodiazepine dosage, and the patients should be appropriately monitored (see <span class="Bold">CLINICAL PHARMACOLOGY</span>, <span class="Bold">Drug Interaction Studies</span>).</p>
<p>Fluconazole increases the AUC of triazolam (single dose) by approximately 50%, C<span class="Sub">max</span> by 20 to 32%, and increases t<span class="Sub">1/2</span> by 25 to 50 % due to the inhibition of metabolism of triazolam. Dosage adjustments of triazolam may be necessary.   </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6ac88932-5c52-449d-bc17-bf3df6e8a742"></a><a name="section-7.2.14"></a><p></p>
<h3><span class="Bold">Oral Contraceptives </span></h3>
<p class="First">Two pharmacokinetic studies with a combined oral contraceptive have been performed using multiple doses of fluconazole. There were no relevant effects on hormone level in the 50 mg fluconazole study, while at 200 mg daily, the AUCs of ethinyl estradiol and levonorgestrel were increased 40% and 24%, respectively. Thus, multiple dose use of fluconazole at these doses is unlikely to have an effect on the efficacy of the combined oral contraceptive. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_41f88772-db06-4433-bef1-abf16f095db2"></a><a name="section-7.2.15"></a><p></p>
<h3><span class="Bold">Pimozide</span></h3>
<p class="First">Although not studied <span class="Italics">in vitro</span> or <span class="Italics">in vivo</span>, concomitant administration of fluconazole with pimozide may result in inhibition of pimozide metabolism. Increased pimozide plasma concentrations can lead to QT prolongation and rare occurrences of <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsade de pointes</span>. Coadministration of fluconazole and pimozide is contraindicated. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_aaeb8ab4-3c22-41ea-979c-116c45b19e7a"></a><a name="section-7.2.16"></a><p></p>
<h3><span class="Bold">Hydrochlorothiazide</span></h3>
<p class="First">In a <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interaction</span> study, coadministration of multiple dose hydrochlorothiazide to healthy volunteers receiving fluconazole increased plasma concentrations of fluconazole by 40%. An effect of this magnitude should not necessitate a change in the fluconazole dose regimen in subjects receiving concomitant diuretics. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7382af55-d532-4775-8ed9-1e201051c899"></a><a name="section-7.2.17"></a><p></p>
<h3><span class="Bold">Alfentanil </span></h3>
<p class="First">A study observed a reduction in clearance and distribution volume as well as prolongation of t<span class="Sub">1/2</span> of alfentanil following concomitant treatment with fluconazole. A possible mechanism of action is fluconazole’s inhibition of CYP3A4. Dosage adjustment of alfentanil may be necessary. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6c3a6752-06c5-4f02-b2e3-346502613458"></a><a name="section-7.2.18"></a><p></p>
<h3><span class="Bold">Amitriptyline, Nortriptyline</span></h3>
<p class="First">Fluconazole increases the effect of amitriptyline and nortriptyline. 5-nortriptyline and/or S-amitriptyline may be measured at initiation of the combination therapy and after one week. Dosage of amitriptyline/nortriptyline should be adjusted, if necessary. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a81a4432-08b2-4341-a848-29b558bafb0f"></a><a name="section-7.2.19"></a><p></p>
<h3><span class="Bold">Amphotericin B</span></h3>
<p class="First">Concurrent administration of fluconazole and amphotericin B in infected normal and immunosuppressed mice showed the following results: a small additive antifungal effect in systemic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> with <span class="Italics">C. albicans</span>, no interaction in intracranial <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> with <span class="Italics"><span class="product-label-link" type="condition" conceptid="440035" conceptname="Cryptococcosis">Cryptococcus neoformans</span></span>, and antagonism of the two drugs in systemic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> with <span class="Italics">A. fumigatus</span>. The clinical significance of results obtained in these studies is unknown. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_dd20a023-bc8f-45fd-b499-e6daa7f0e220"></a><a name="section-7.2.20"></a><p></p>
<h3><span class="Bold">Azithromycin</span></h3>
<p class="First">An open-label, randomized, three-way crossover study in 18 healthy subjects assessed the effect of a single 1200 mg oral dose of azithromycin on the pharmacokinetics of a single 800 mg oral dose of fluconazole as well as the effects of fluconazole on the pharmacokinetics of azithromycin. There was no significant <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interaction</span> between fluconazole and azithromycin. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_76d0678e-5048-4887-a2a9-5d4f80420792"></a><a name="section-7.2.21"></a><p></p>
<h3><span class="Bold">Carbamazepine</span></h3>
<p class="First">Fluconazole inhibits the metabolism of carbamazepine and an increase in serum carbamazepine of 30% has been observed. There is a risk of developing carbamazepine toxicity. Dosage adjustment of carbamazepine may be necessary depending on concentration measurements/effect. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_dd484fad-b9f2-4892-ac19-de3777dbaf0d"></a><a name="section-7.2.22"></a><p></p>
<h3><span class="Bold">Calcium Channel Blockers</span></h3>
<p class="First">Certain dihydropyridine calcium channel antagonists (nifedipine, isradipine, amlodipine, and felodipine) are metabolized by CYP3A4. Fluconazole has the potential to increase the systemic exposure of the calcium channel antagonists. Frequent monitoring for adverse events is recommended. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0ceb393f-5bab-4199-b21b-f25f7c11487b"></a><a name="section-7.2.23"></a><p></p>
<h3><span class="Bold">Celecoxib </span></h3>
<p class="First">During concomitant treatment with fluconazole (200 mg daily) and celecoxib (200 mg), the celecoxib C<span class="Sub">max</span> and AUC increased by 68% and 134%, respectively. Half of the celecoxib dose may be necessary when combined with fluconazole. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_363a582e-dea9-47f7-98ea-fd96959ca344"></a><a name="section-7.2.24"></a><p></p>
<h3><span class="Bold">Cyclophosphamide  </span></h3>
<p class="First">Combination therapy with cyclophosphamide and fluconazole results in an increase in serum bilirubin and serum creatinine. The combination may be used while taking increased consideration to the risk of increased serum bilirubin and serum creatinine. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9223bf0c-7a7c-4632-996b-73a5b1a92bff"></a><a name="section-7.2.25"></a><p></p>
<h3><span class="Bold">Fentanyl</span></h3>
<p class="First">One fatal case of possible fentanyl fluconazole interaction was reported. The author judged that the patient died from fentanyl <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span>. Furthermore, in a randomized crossover study with 12 healthy volunteers it was shown that fluconazole delayed the elimination of fentanyl significantly. Elevated fentanyl concentration may lead to <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_57d8d587-235b-4020-8d57-7badd5cc590c"></a><a name="section-7.2.26"></a><p></p>
<h3><span class="Bold">Halofantrine</span></h3>
<p class="First">Fluconazole can increase halofantrine plasma concentration due to an inhibitory effect on CYP3A4. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0596ece5-2863-45c9-bc9c-15e414e63035"></a><a name="section-7.2.27"></a><p></p>
<h3><span class="Bold">HMG-CoA Reductase Inhibitors  </span></h3>
<p class="First">The risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> and <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> increases when fluconazole is coadministered with HMG-CoA reductase inhibitors metabolized through CYP3A4, such as atorvastatin and simvastatin, or through CYP2C9, such as fluvastatin. If concomitant therapy is necessary, the patient should be observed for symptoms of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> and <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> and creatinine kinase should be monitored. HMG-CoA reductase inhibitors should be discontinued if a marked increase in creatinine kinase is observed or <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>/<span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> is diagnosed or suspected. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0d0edd7b-74a5-4965-843f-16b4a7b1e6e2"></a><a name="section-7.2.28"></a><p></p>
<h3><span class="Bold">Losartan</span></h3>
<p class="First">Fluconazole inhibits the metabolism of losartan to its active metabolite (E-31 74) which is responsible for most of the angiotensin II-receptor antagonism which occurs during treatment with losartan. Patients should have their blood pressure monitored continuously. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6b7d6df5-f40e-4921-b6aa-d38abf4661b3"></a><a name="section-7.2.29"></a><p></p>
<h3><span class="Bold">Methadone </span></h3>
<p class="First">Fluconazole may enhance the serum concentration of methadone. Dosage adjustment of methadone may be necessary. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5fe297f3-b4ef-42f0-a606-a16543644309"></a><a name="section-7.2.30"></a><p></p>
<h3><span class="Bold">Non-Steroidal Anti-Inflammatory Drugs</span></h3>
<p class="First">The C<span class="Sub">max</span> and AUC of flurbiprofen were increased by 23% and 81%, respectively, when coadministered with fluconazole compared to administration of flurbiprofen alone. Similarly, the C<span class="Sub">max</span> and AUC of the pharmacologically active isomer [S-(+)-ibuprofen] were increased by 15% and 82%, respectively, when fluconazole was coadministered with racemic ibuprofen (400 mg) compared to administration of racemic ibuprofen alone. </p>
<p>Although not specifically studied, fluconazole has the potential to increase the systemic exposure of other NSAIDs that are metabolized by CYP2C9 (e.g., naproxen, lornoxicam, meloxicam, diclofenac). Frequent monitoring for adverse events and toxicity related to NSAIDs is recommended. Adjustment of dosage of NSAIDs may be needed. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_78895d58-b3be-4930-bfc3-07789323d046"></a><a name="section-7.2.31"></a><p></p>
<h3><span class="Bold">Prednisone</span></h3>
<p class="First">There was a case report that a liver-transplanted patient treated with prednisone developed acute <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">adrenal cortex insufficiency</span> when a three month therapy with fluconazole was discontinued. The discontinuation of fluconazole presumably caused an enhanced CYP3A4 activity which led to increased metabolism of prednisone. Patients on long-term treatment with fluconazole and prednisone should be carefully monitored for <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">adrenal cortex insufficiency</span> when fluconazole is discontinued. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3fb1b7bc-8fe9-4377-ad08-6bbe497ec933"></a><a name="section-7.2.32"></a><p></p>
<h3><span class="Bold">Saquinavir  </span></h3>
<p class="First">Fluconazole increases the AUC of saquinavir by approximately 50%, C<span class="Sub">max</span> by approximately 55%, and decreases clearance of saquinavir by approximately 50% due to inhibition of saquinavir’s hepatic metabolism by CYP3A4 and inhibition of P-glycoprotein. Dosage adjustment of saquinavir may be necessary. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b3f55f17-6e89-4270-acec-d35bc0d303df"></a><a name="section-7.2.33"></a><p></p>
<h3><span class="Bold">Sirolimus  </span></h3>
<p class="First">Fluconazole increases plasma concentrations of sirolimus presumably by inhibiting the metabolism of sirolimus via CYP3A4 and P-glycoprotein. This combination may be used with a dosage adjustment of sirolimus depending on the effect/concentration measurements. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2c711239-d31a-4a3f-9745-638866dc3585"></a><a name="section-7.2.34"></a><p></p>
<h3><span class="Bold">Vinca Alkaloids</span></h3>
<p class="First">Although not studied, fluconazole may increase the plasma levels of the vinca alkaloids (e.g., vincristine and vinblastine) and lead to <span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">neurotoxicity</span>, which is possibly due to an inhibitory effect on CYP3A4. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b978dd29-9bb4-4fdb-8c12-f1dfee46dca5"></a><a name="section-7.2.35"></a><p></p>
<h3><span class="Bold">Vitamin A  </span></h3>
<p class="First">Based on a case report in one patient receiving combination therapy with all-transretinoid acid (an acid form of vitamin A) and fluconazole, CNS related undesirable effects have developed in the form of pseudotumour cerebri, which disappeared after discontinuation of fluconazole treatment. This combination may be used but the incidence of CNS related undesirable effects should be borne in mind. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5e556a15-03b7-4e7d-8900-31e0b261ba53"></a><a name="section-7.2.36"></a><p></p>
<h3><span class="Bold">Zidovudine</span></h3>
<p class="First">Fluconazole increases C<span class="Sub">max</span> and AUC of zidovudine by 84% and 74%, respectively, due to an approximately 45% decrease in oral zidovudine clearance. The half-life of zidovudine was likewise prolonged by approximately 128% following combination therapy with fluconazole. Patients receiving this combination should be monitored for the development of zidovudine-related adverse reactions. Dosage reduction of zidovudine may be considered. </p>
<p>Physicians should be aware that interaction studies with medications other than those listed in the <span class="Bold">CLINICAL PHARMACOLOGY</span> section have not been conducted, but such interactions may occur.</p>
</div>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_8c64c9bc-3e1c-4ca7-93c2-74e3a75a81dc"></a><a name="section-7.3"></a><p></p>
<h2>Carcinogenesis, Mutagenesis and Impairment of Fertility</h2>
<p class="First">Fluconazole showed no evidence of carcinogenic potential in mice and rats treated orally for 24 months at doses of 2.5, 5, or 10 mg/kg/day (approximately 2 to 7x the recommended human dose). Male rats treated with 5 and 10 mg/kg/day had an increased incidence of <span class="product-label-link" type="condition" conceptid="4301500" conceptname="Liver cell adenoma">hepatocellular adenomas</span>.</p>
<p>Fluconazole, with or without metabolic activation, was negative in tests for mutagenicity in 4 <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">S. typhimurium, </span>and in the mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> L5178Y system. Cytogenetic studies <span class="Italics">in vivo </span>(murine bone marrow cells, following oral administration of fluconazole) and <span class="Italics">in vitro </span>(human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> exposed to fluconazole at 1000 mcg/mL) showed no evidence of chromosomal mutations.</p>
<p>Fluconazole did not affect the fertility of male or female rats treated orally with daily doses of 5, 10, or 20 mg/kg or with parenteral doses of 5, 25, or 75 mg/kg, although the onset of parturition was slightly delayed at 20 mg/kg PO. In an intravenous perinatal study in rats at 5, 20, and 40 mg/kg, dystocia and prolongation of parturition were observed in a few dams at 20 mg/kg (approximately 5 to 15x the recommended human dose) and 40 mg/kg, but not at 5 mg/kg. The disturbances in parturition were reflected by a slight increase in the number of still-born pups and decrease of neonatal survival at these dose levels. The effects on parturition in rats are consistent with the species specific estrogen-lowering property produced by high doses of fluconazole. Such a hormone change has not been observed in women treated with fluconazole (see <span class="Bold">CLINICAL PHARMACOLOGY</span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_cba6c0bb-7ed8-4a14-a50f-7a3d428b5145"></a><a name="section-7.4"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_aa3f0a4c-6f8a-4ae6-91af-1b28e868f9db"></a><a name="section-7.4.1"></a><p></p>
<h3>Teratogenic Effects</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_fa22f7f2-e3dd-4dd5-b6e0-03213f393d01"></a><a name="section-7.4.1.1"></a><p></p>
<h4>Pregnancy Category D</h4>
<p class="First">A few published case reports describe a rare pattern of distinct congenital anomalies in infants exposed <span class="Italics">in utero</span> to high dose maternal fluconazole (400 to 800 mg/day) during most or all of the first trimester. These reported anomalies are similar to those seen in animal studies. If this drug is used during pregnancy, or if the patient becomes pregnant while taking the drug, the patient should be informed of the potential hazard to the fetus (see <span class="Bold">WARNINGS, Use in Pregnancy</span>).</p>
<p><span class="Italics">Human Data </span></p>
<p>Several published epidemiologic studies do not suggest an increased risk of congenital anomalies associated with low dose exposure to fluconazole in pregnancy (most subjects received a single oral dose of 150 mg). A few published case reports describe a distinctive and rare pattern of <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> among infants whose mothers received high dose (400 to 800 mg/day) fluconazole during most or all of the first trimester of pregnancy. The features seen in these infants include: <span class="product-label-link" type="condition" conceptid="4029307" conceptname="Brachycephaly">brachycephaly</span>, abnormal facies, abnormal calvarial development, <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palate</span>, femoral bowing, thin ribs and long bones, arthrogryposis, and congenital heart disease. These effects are similar to those seen in animal studies. </p>
<p><span class="Italics">Animal Data </span></p>
<p>Fluconazole was administered orally to pregnant rabbits during organogenesis in two studies at doses of 5, 10, and 20 mg/kg and at 5, 25, and 75 mg/kg, respectively. Maternal <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> was impaired at all dose levels (approximately 0.25 to 4 times the 400 mg clinical dose based on BSA), and abortions occurred at 75 mg/kg (approximately 4 times the 400 mg clinical dose based on BSA); no adverse fetal effects were observed. </p>
<p>In several studies in which pregnant rats received fluconazole orally during organogenesis, maternal <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> was impaired and placental weights were increased at 25 mg/kg. There were no fetal effects at 5 or 10 mg/kg; increases in fetal anatomical variants (supernumerary ribs, renal pelvis dilation) and delays in ossification were observed at 25 and 50 mg/kg and higher doses. At doses ranging from 80 to 320 mg/kg (approximately 2 to 8 times the 400 mg clinical dose based on BSA), embryolethality in rats was increased and fetal abnormalities included wavy ribs, <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palate</span>, and abnormal cranio-facial ossification. These effects are consistent with the inhibition of estrogen synthesis in rats and may be a result of known effects of lowered estrogen on pregnancy, organogenesis, and parturition.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3236fdb8-6472-42f1-962f-507dd3022ca4"></a><a name="section-7.5"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Fluconazole is secreted in human milk at concentrations similar to maternal plasma concentrations. Caution should be exercised when fluconazole is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9035ff59-b39e-48c4-b417-b1648df7702b"></a><a name="section-7.6"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">An open-label, randomized, controlled trial has shown fluconazole to be effective in the treatment of <span class="product-label-link" type="condition" conceptid="4080451" conceptname="Pharyngeal candidiasis">oropharyngeal candidiasis</span> in children 6 months to 13 years of age (see <span class="Bold">CLINICAL STUDIES</span>).</p>
<p>The use of fluconazole in children with <span class="product-label-link" type="condition" conceptid="432310" conceptname="Cryptococcal meningitis">cryptococcal meningitis</span>, <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> </span><span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span>, or systemic <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> </span><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> is supported by the efficacy shown for these indications in adults and by the results from several small noncomparative pediatric clinical studies. In addition, pharmacokinetic studies in children (see <span class="Bold">CLINICAL PHARMACOLOGY</span>) have established a dose proportionality between children and adults (see <span class="Bold">DOSAGE AND ADMINISTRATION</span>). </p>
<p>In a noncomparative study of children with serious systemic <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span>, most of which were <span class="product-label-link" type="condition" conceptid="438077" conceptname="Invasive candidiasis">candidemia</span>, the effectiveness of fluconazole was similar to that reported for the treatment of <span class="product-label-link" type="condition" conceptid="438077" conceptname="Invasive candidiasis">candidemia</span> in adults. Of 17 subjects with culture-confirmed <span class="product-label-link" type="condition" conceptid="438077" conceptname="Invasive candidiasis">candidemia</span>, 11 of 14 (79%) with baseline symptoms (3 were asymptomatic) had a clinical cure; 13/15 (87%) of evaluable patients had a mycologic cure at the end of treatment but two of these patients relapsed at 10 and 18 days, respectively, following cessation of therapy.</p>
<p>The efficacy of fluconazole for the suppression of <span class="product-label-link" type="condition" conceptid="432310" conceptname="Cryptococcal meningitis">cryptococcal meningitis</span> was successful in 4 of 5 children treated in a compassionate-use study of fluconazole for the treatment of life-threatening or serious <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">mycosis</span>. There is no information regarding the efficacy of fluconazole for primary treatment of <span class="product-label-link" type="condition" conceptid="432310" conceptname="Cryptococcal meningitis">cryptococcal meningitis</span> in children.</p>
<p>The safety profile of fluconazole in children has been studied in 577 children ages 1 day to 17 years who received doses ranging from 1 to 15 mg/kg/day for 1 to 1,616 days (see <span class="Bold">ADVERSE REACTIONS</span>).</p>
<p>Efficacy of fluconazole has not been established in infants less than 6 months of age (see <span class="Bold">CLINICAL PHARMACOLOGY</span>). A small number of patients (29) ranging in age from 1 day to 6 months have been treated safely with fluconazole.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8af2269d-b273-4d26-a494-24f4c587cc32"></a><a name="section-7.7"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">In non-AIDS patients, side effects possibly related to fluconazole treatment were reported in fewer patients aged 65 and older (9%, n = 339) than for younger patients (14%, n = 2240). However, there was no consistent difference between the older and younger patients with respect to individual side effects. Of the most frequently reported (&gt; 1%) side effects, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> occurred in greater proportions of older patients. Similar proportions of older patients (2.4%) and younger patients (1.5%) discontinued fluconazole therapy because of side effects. In postmarketing experience, spontaneous reports of <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> and <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> were more frequent among patients 65 years of age or older than in those between 12 and 65 years of age. Because of the voluntary nature of the reports and the natural increase in the incidence of <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> and <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> in the elderly, it is however not possible to establish a casual relationship to drug exposure.</p>
<p>Controlled clinical trials of fluconazole did not include sufficient numbers of patients aged 65 and older to evaluate whether they respond differently from younger patients in each indication. Other reported clinical experience has not identified differences in responses between the elderly and younger patients.</p>
<p>Fluconazole is primarily cleared by renal excretion as unchanged drug. Because elderly patients are more likely to have decreased renal function, care should be taken to adjust dose based on creatinine clearance. It may be useful to monitor renal function (see <span class="Bold">CLINICAL PHARMACOLOGY</span> and <span class="Bold">DOSAGE AND ADMINISTRATION</span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_c1ddb803-6616-424a-ae95-3021545759b1"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Fluconazole is generally well tolerated.</p>
<p>In some patients, particularly those with serious underlying diseases such as AIDS and cancer, changes in renal and hematological function test results and hepatic abnormalities have been observed during treatment with fluconazole and comparative agents, but the clinical significance and relationship to treatment is uncertain.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_545928be-6d76-4c29-b45a-ed88f10463db"></a><a name="section-8.1"></a><p></p>
<h2>In Patients Receiving Multiple Doses for Other <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></h2>
<p class="First">Sixteen percent of over 4000 patients treated with fluconazole in clinical trials of 7 days or more experienced adverse events. Treatment was discontinued in 1.5% of patients due to adverse clinical events and in 1.3% of patients due to laboratory test abnormalities.</p>
<p>Clinical adverse events were reported more frequently in HIV infected patients (21%) than in non-HIV infected patients (13%); however, the patterns in HIV infected and non-HIV infected patients were similar. The proportions of patients discontinuing therapy due to clinical adverse events were similar in the two groups (1.5%).</p>
<p>The following treatment-related clinical adverse events occurred at an incidence of 1% or greater in 4048 patients receiving fluconazole for 7 or more days in clinical trials: <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> 3.7%, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> 1.9%, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> 1.8%, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> 1.7%, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> 1.7%, and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> 1.5%.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_aaecf70d-d3a9-49f7-8933-e3e1cb04c275"></a><a name="section-8.1.1"></a><p></p>
<h3>Hepatobiliary</h3>
<p class="First">In combined clinical trials and marketing experience, there have been rare cases of serious hepatic reactions during treatment with fluconazole (see <span class="Bold">WARNINGS</span>). The spectrum of these hepatic reactions has ranged from mild transient elevations in transaminases to clinical <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="4143915" conceptname="Cholestasis">cholestasis</span> and <span class="product-label-link" type="condition" conceptid="4026032" conceptname="Acute hepatic failure">fulminant hepatic failure</span>, including fatalities. Instances of fatal hepatic reactions were noted to occur primarily in patients with serious underlying medical conditions (predominantly AIDS or malignancy) and often while taking multiple concomitant medications. Transient hepatic reactions, including <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> and <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, have occurred among patients with no other identifiable risk factors. In each of these cases, liver function returned to baseline on discontinuation of fluconazole.</p>
<p>In two comparative trials evaluating the efficacy of fluconazole for the suppression of relapse of <span class="product-label-link" type="condition" conceptid="432310" conceptname="Cryptococcal meningitis">cryptococcal meningitis</span>, a statistically significant increase was observed in median AST (<span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>) levels from a baseline value of 30 IU/L to 41 IU/L in one trial and 34 IU/L to 66 IU/L in the other. The overall rate of serum transaminase elevations of more than 8 times the upper limit of normal was approximately 1% in fluconazole-treated patients in clinical trials. These elevations occurred in patients with severe underlying disease, predominantly AIDS or malignancies, most of whom were receiving multiple concomitant medications, including many known to be hepatotoxic. The incidence of abnormally elevated serum transaminases was greater in patients taking fluconazole concomitantly with one or more of the following medications: rifampin, phenytoin, isoniazid, valproic acid, or oral sulfonylurea hypoglycemic agents.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0d23d4ec-b457-428e-a622-42c8370a1ca6"></a><a name="section-8.2"></a><p></p>
<h2>Postmarketing Experience</h2>
<p class="First">In addition, the following adverse events have occurred during postmarketing experience.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c7c7bf2c-497d-43d2-9ffa-69e5a4b8710b"></a><a name="section-8.2.1"></a><p></p>
<h3>Immunologic</h3>
<p class="First">In rare cases, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> (including <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, face <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> and <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>) has been reported.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_aa00652e-2811-42cb-bc6b-5ec91a821a5b"></a><a name="section-8.2.2"></a><p></p>
<h3>Body as a Whole</h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_66a2745e-2c93-43ad-9913-a3ee6bfa0782"></a><a name="section-8.2.3"></a><p></p>
<h3>Cardiovascular</h3>
<p class="First">QT prolongation, <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsade de pointes</span> (see <span class="Bold">PRECAUTIONS</span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ab71ac59-fe3b-4219-a142-da09352cb264"></a><a name="section-8.2.4"></a><p></p>
<h3>Central Nervous System</h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_dd8c1456-d7aa-49c0-81df-339dbbe04140"></a><a name="section-8.2.5"></a><p></p>
<h3>Hematopoietic and Lymphatic</h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span>, including <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> and <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_02fe880a-db68-423b-b979-43ddd799fb09"></a><a name="section-8.2.6"></a><p></p>
<h3>Metabolic</h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">Hypercholesterolemia</span>, <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span>, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8293ce38-6b7c-4f1e-986b-aa415b444bdb"></a><a name="section-8.2.7"></a><p></p>
<h3>Gastrointestinal</h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="4143915" conceptname="Cholestasis">Cholestasis</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">hepatocellular damage</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0e72ab97-6478-4b3f-9a8f-5bf62188f044"></a><a name="section-8.2.8"></a><p></p>
<h3>Other Senses</h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">Taste perversion</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_76d45f5a-b364-47b4-b2b8-3471eaf2455c"></a><a name="section-8.2.9"></a><p></p>
<h3>Musculoskeletal System</h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c5627c9f-87e6-4c84-b69c-50c04873cbc9"></a><a name="section-8.2.10"></a><p></p>
<h3>Nervous System</h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3db5c377-c43d-45ac-9a30-7794af430c37"></a><a name="section-8.2.11"></a><p></p>
<h3>Skin and Appendages</h3>
<p class="First">Acute generalized exanthematous-pustulosis, <span class="product-label-link" type="condition" conceptid="4080559" conceptname="Baboon syndrome">drug eruption</span>, increased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, exfoliative <span class="product-label-link" type="condition" conceptid="140842" conceptname="Changes in skin texture">skin disorders</span> including <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span> and <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> (see <span class="Bold">WARNINGS</span>), <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8fa64fd6-8cdc-4b35-855f-9377933ed7d8"></a><a name="section-8.3"></a><p></p>
<h2>Adverse Reactions in Children</h2>
<p class="First">The pattern and incidence of adverse events and laboratory abnormalities recorded during pediatric clinical trials are comparable to those seen in adults.</p>
<p>In Phase II/III clinical trials conducted in the United States and in Europe, 577 pediatric patients, ages 1 day to 17 years were treated with fluconazole at doses up to 15 mg/kg/day for up to 1,616 days. Thirteen percent of children experienced treatment related adverse events. The most commonly reported events were <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (5%), <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> (3%), <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (2%), and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (2%). Treatment was discontinued in 2.3% of patients due to adverse clinical events and in 1.4% of patients due to laboratory test abnormalities. The majority of treatment-related laboratory abnormalities were elevations of transaminases or alkaline phosphatase.</p>
<p><span class="Bold">Percentage of Patients With Treatment-Related Side Effects</span></p>
<a name="id_c8581fb9-edf8-4235-a3d5-e55a476d0f60"></a><table border="single" width="442.000">
<col width="32.8%">
<col width="33.5%">
<col width="33.7%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><span class="Bold"> </span></td>
<td class="Botrule Rrule" align="center" valign="middle">
<p class="First"><span class="Bold">Fluconazole</span></p>
<span class="Bold">(n = 577)</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle">
<p class="First"><span class="Bold">Comparative Agents</span></p>
<span class="Bold">(n = 451)</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"> With any side effect </td>
<td class="Botrule Rrule" align="center" valign="middle"> 13 </td>
<td class="Botrule Rrule" align="center" valign="middle"> 9.3 </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"> <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> </td>
<td class="Botrule Rrule" align="center" valign="middle"> 5.4 </td>
<td class="Botrule Rrule" align="center" valign="middle"> 5.1 </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"> <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span> </td>
<td class="Botrule Rrule" align="center" valign="middle"> 2.8 </td>
<td class="Botrule Rrule" align="center" valign="middle"> 1.6 </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"> <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> </td>
<td class="Botrule Rrule" align="center" valign="middle"> 2.3 </td>
<td class="Botrule Rrule" align="center" valign="middle"> 1.6 </td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="middle"> <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> </td>
<td class="Rrule" align="center" valign="middle"> 2.1 </td>
<td class="Botrule Rrule" align="center" valign="middle"> 2.2 </td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_73e5836e-6919-4c23-9e8e-2d473e0b2ef0"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">There have been reports of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with fluconazole accompanied by <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucination</span> and paranoid behavior.</p>
<p>In the event of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, symptomatic treatment (with supportive measures and gastric lavage if clinically indicated) should be instituted.</p>
<p>Fluconazole is largely excreted in urine. A three hour hemodialysis session decreases plasma levels by approximately 50%.</p>
<p>In mice and rats receiving very high doses of fluconazole, clinical effects in both species included decreased motility and respiration, <span class="product-label-link" type="condition" conceptid="373194" conceptname="Paralytic ptosis">ptosis</span>, <span class="product-label-link" type="condition" conceptid="435553" conceptname="Epiphora">lacrimation</span>, <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">salivation</span>, <span class="product-label-link" type="condition" conceptid="197672" conceptname="Urinary incontinence">urinary incontinence</span>, loss of righting reflex and <span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">cyanosis</span>; <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> was sometimes preceded by <span class="product-label-link" type="condition" conceptid="4265182" conceptname="Clonic seizure">clonic convulsions</span>.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_77387fc5-cff8-47da-80f1-5e639433408d"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6a254b12-3dbf-4a5d-bd18-83c69a6b4071"></a><a name="section-10.1"></a><p></p>
<h2>Dosage and Administration in Adults</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_789413f3-5eda-4ae2-aaba-9fa2df84171e"></a><a name="section-10.1.1"></a><p></p>
<h3>Multiple Dose</h3>
<p class="First">SINCE ORAL ABSORPTION IS RAPID AND ALMOST COMPLETE, THE DAILY DOSE OF FLUCONAZOLE IS THE SAME FOR ORAL (TABLETS AND SUSPENSION) AND INTRAVENOUS ADMINISTRATION. In general, a loading dose of twice the daily dose is recommended on the first day of therapy to result in plasma concentrations close to steady-state by the second day of therapy.</p>
<p>The daily dose of fluconazole for the treatment of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> other than <span class="product-label-link" type="condition" conceptid="198363" conceptname="Candidiasis of vagina">vaginal candidiasis</span> should be based on the infecting organism and the patient’s response to therapy. Treatment should be continued until clinical parameters or laboratory tests indicate that active <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infection</span> has subsided. An inadequate period of treatment may lead to recurrence of active <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. Patients with AIDS and <span class="product-label-link" type="condition" conceptid="432310" conceptname="Cryptococcal meningitis">cryptococcal meningitis</span> or recurrent <span class="product-label-link" type="condition" conceptid="4080451" conceptname="Pharyngeal candidiasis">oropharyngeal candidiasis</span> usually require maintenance therapy to prevent relapse.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b9f04c26-ebca-4b47-9e0a-c5b33344ea17"></a><a name="section-10.1.1.1"></a><p></p>
<h4><span class="product-label-link" type="condition" conceptid="4080451" conceptname="Pharyngeal candidiasis">Oropharyngeal Candidiasis</span></h4>
<p class="First">The recommended dosage of fluconazole for <span class="product-label-link" type="condition" conceptid="4080451" conceptname="Pharyngeal candidiasis">oropharyngeal candidiasis</span> is 200 mg on the first day, followed by 100 mg once daily. Clinical evidence of <span class="product-label-link" type="condition" conceptid="4080451" conceptname="Pharyngeal candidiasis">oropharyngeal candidiasis</span> generally resolves within several days, but treatment should be continued for at least 2 weeks to decrease the likelihood of relapse.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d6f634a1-154d-4077-934f-844f33cc70e0"></a><a name="section-10.1.1.2"></a><p></p>
<h4><span class="product-label-link" type="condition" conceptid="28974" conceptname="Candidiasis of the esophagus">Esophageal Candidiasis</span></h4>
<p class="First">The recommended dosage of fluconazole for <span class="product-label-link" type="condition" conceptid="28974" conceptname="Candidiasis of the esophagus">esophageal candidiasis</span> is 200 mg on the first day, followed by 100 mg once daily. Doses up to 400 mg/day may be used, based on medical judgment of the patient’s response to therapy. Patients with <span class="product-label-link" type="condition" conceptid="28974" conceptname="Candidiasis of the esophagus">esophageal candidiasis</span> should be treated for a minimum of three weeks and for at least two weeks following resolution of symptoms.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_cc3cd0cd-6048-450b-aadb-5f053f50e005"></a><a name="section-10.1.1.3"></a><p></p>
<h4>Systemic <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></h4>
<p class="First">For systemic <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> </span><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> including <span class="product-label-link" type="condition" conceptid="438077" conceptname="Invasive candidiasis">candidemia</span>, <span class="product-label-link" type="condition" conceptid="438077" conceptname="Invasive candidiasis">disseminated candidiasis</span>, and <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, optimal therapeutic dosage and duration of therapy have not been established. In open, noncomparative studies of small numbers of patients, doses of up to 400 mg daily have been used.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2adf3acd-a446-47a4-abc9-2e45a324f848"></a><a name="section-10.1.1.4"></a><p></p>
<h4><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infections</span> and <span class="product-label-link" type="condition" conceptid="196152" conceptname="Peritonitis">Peritonitis</span></h4>
<p class="First">For the treatment of <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> </span><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span> and <span class="product-label-link" type="condition" conceptid="196152" conceptname="Peritonitis">peritonitis</span>, daily doses of 50 to 200 mg have been used in open, noncomparative studies of small numbers of patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_fd3015f7-9a99-4ea1-a517-4483e1f9f6c6"></a><a name="section-10.1.1.5"></a><p></p>
<h4><span class="product-label-link" type="condition" conceptid="432310" conceptname="Cryptococcal meningitis">Cryptococcal Meningitis</span></h4>
<p class="First">The recommended dosage for treatment of acute <span class="product-label-link" type="condition" conceptid="432310" conceptname="Cryptococcal meningitis">cryptococcal meningitis</span> is 400 mg on the first day, followed by 200 mg once daily. A dosage of 400 mg once daily may be used, based on medical judgment of the patient’s response to therapy. The recommended duration of treatment for initial therapy of <span class="product-label-link" type="condition" conceptid="432310" conceptname="Cryptococcal meningitis">cryptococcal meningitis</span> is 10 to 12 weeks after the cerebrospinal fluid becomes culture negative. The recommended dosage of fluconazole for suppression of relapse of <span class="product-label-link" type="condition" conceptid="432310" conceptname="Cryptococcal meningitis">cryptococcal meningitis</span> in patients with AIDS is 200 mg once daily.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_01adfd39-d24c-4d04-8c08-a2cd1098ba9f"></a><a name="section-10.1.1.6"></a><p></p>
<h4>Prophylaxis in Patients Undergoing Bone Marrow Transplantation</h4>
<p class="First">The recommended fluconazole daily dosage for the prevention of <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">candidiasis</span> in patients undergoing bone marrow transplantation is 400 mg, once daily. Patients who are anticipated to have severe <span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">granulocytopenia</span> (less than 500 <span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">neutrophils</span> per cu mm) should start fluconazole prophylaxis several days before the anticipated onset of <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, and continue for 7 days after the neutrophil count rises above 1000 cells per cu mm.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e7f51da8-a008-4451-9ebd-206e538556ec"></a><a name="section-10.2"></a><p></p>
<h2>Dosage and Administration in Children</h2>
<p class="First">The following dose equivalency scheme should generally provide equivalent exposure in pediatric and adult patients:</p>
<a name="id_7d102a75-0f99-41dd-b7b2-11e08de2560f"></a><table border="single" width="343.000">
<col width="54.5%">
<col width="45.5%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold"><span class="Underline">Pediatric Patients</span></span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold"><span class="Underline">Adults</span></span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top"> 3 mg/kg </td>
<td class="Botrule Rrule" align="center" valign="top"> 100 mg </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top"> 6 mg/kg </td>
<td class="Botrule Rrule" align="center" valign="top"> 200 mg </td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" valign="top"> 12<span class="Sup">*</span> mg/kg </td>
<td class="Botrule Rrule" align="center" valign="top"> 400 mg </td>
</tr>
</tbody>
</table>
<p><span class="Sup">* </span>Some older children may have clearances similar to that of adults. Absolute doses exceeding 600 mg/day are not recommended.</p>
<p>Experience with fluconazole in neonates is limited to pharmacokinetic studies in premature newborns (see <span class="Bold">CLINICAL PHARMACOLOGY</span>). Based on the prolonged half-life seen in premature newborns (gestational age 26 to 29 weeks), these children, in the first two weeks of life, should receive the same dosage (mg/kg) as in older children, but administered every 72 hours. After the first two weeks, these children should be dosed once daily. No information regarding fluconazole pharmacokinetics in full-term newborns is available.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9b76e8df-a029-4002-b66b-af6081a79ee8"></a><a name="section-10.2.1"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="4080451" conceptname="Pharyngeal candidiasis">Oropharyngeal Candidiasis</span></h3>
<p class="First">The recommended dosage of fluconazole for <span class="product-label-link" type="condition" conceptid="4080451" conceptname="Pharyngeal candidiasis">oropharyngeal candidiasis</span> in children is 6 mg/kg on the first day, followed by 3 mg/kg once daily. Treatment should be administered for at least 2 weeks to decrease the likelihood of relapse.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6f7e81a1-f39d-478e-996b-cbe20c87d828"></a><a name="section-10.2.2"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="28974" conceptname="Candidiasis of the esophagus">Esophageal Candidiasis</span></h3>
<p class="First">For the treatment of <span class="product-label-link" type="condition" conceptid="28974" conceptname="Candidiasis of the esophagus">esophageal candidiasis</span>, the recommended dosage of fluconazole in children is 6 mg/kg on the first day, followed by 3 mg/kg once daily. Doses up to 12 mg/kg/day may be used, based on medical judgment of the patient’s response to therapy. Patients with <span class="product-label-link" type="condition" conceptid="28974" conceptname="Candidiasis of the esophagus">esophageal candidiasis</span> should be treated for a minimum of three weeks and for at least 2 weeks following the resolution of symptoms.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_558da71d-06ac-4d96-8ee8-b5f38f6b51c2"></a><a name="section-10.2.3"></a><p></p>
<h3>Systemic <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></h3>
<p class="First">For the treatment of <span class="product-label-link" type="condition" conceptid="438077" conceptname="Invasive candidiasis">candidemia</span> and disseminated <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> </span><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, daily doses of 6 to 12 mg/kg/day have been used in an open, noncomparative study of a small number of children.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0d61a9c1-5a3f-40c1-8cbd-a9784c5a3d41"></a><a name="section-10.2.4"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="432310" conceptname="Cryptococcal meningitis">Cryptococcal Meningitis</span></h3>
<p class="First">For the treatment of acute <span class="product-label-link" type="condition" conceptid="432310" conceptname="Cryptococcal meningitis">cryptococcal meningitis</span>, the recommended dosage is 12 mg/kg on the first day, followed by 6 mg/kg once daily. A dosage of 12 mg/kg once daily may be used, based on medical judgment of the patient’s response to therapy. The recommended duration of treatment for initial therapy of <span class="product-label-link" type="condition" conceptid="432310" conceptname="Cryptococcal meningitis">cryptococcal meningitis</span> is 10 to 12 weeks after the cerebrospinal fluid becomes culture negative. For suppression of relapse of <span class="product-label-link" type="condition" conceptid="432310" conceptname="Cryptococcal meningitis">cryptococcal meningitis</span> in children with AIDS, the recommended dose of fluconazole is 6 mg/kg once daily.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_47e62bf8-b126-4dd8-ad21-bed55e280d26"></a><a name="section-10.3"></a><p></p>
<h2>Dosage In Patients With <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span></h2>
<p class="First">Fluconazole is cleared primarily by renal excretion as unchanged drug. In patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> who will receive multiple doses of fluconazole, an initial loading dose of 50 to 400 mg should be given. After the loading dose, the daily dose (according to indication) should be based on the following table:</p>
<a name="id_16384519-ab14-4e2b-815d-011d8069c739"></a><table border="single" width="443.000">
<col width="49.4%">
<col width="50.6%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><span class="Bold"><span class="Underline">Creatinine Clearance (mL/min)</span></span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold"><span class="Underline">Percent of Recommended Dose</span></span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle"> &gt; 50 </td>
<td class="Botrule Rrule" align="center" valign="middle"> 100% </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle"> ≤ 50 (no dialysis) </td>
<td class="Botrule Rrule" align="center" valign="middle"> 50% </td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" valign="middle"> Regular dialysis </td>
<td class="Botrule Rrule" align="center" valign="middle"> 100% after each dialysis </td>
</tr>
</tbody>
</table>
<p>These are suggested dose adjustments based on pharmacokinetics following administration of multiple doses. Further adjustment may be needed depending upon clinical condition.</p>
<p>When serum creatinine is the only measure of renal function available, the following formula (based on sex, weight, and age of the patient) should be used to estimate the creatinine clearance in adults:</p>
<p>Males: <span class="Underline"> Weight (kg) × (140-age) </span></p>
<p>        72 × serum creatinine (mg/100 mL)</p>
<p>Females: 0.85 × above value</p>
<p>Although the pharmacokinetics of fluconazole USP has not been studied in children with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>, dosage reduction in children with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> should parallel that recommended for adults. The following formula may be used to estimate creatinine clearance in children:</p>
<p>K × <span class="Underline"> linear length or height (cm) </span></p>
<p>      serum creatinine (mg/100 mL)</p>
<p>(Where K = 0.55 for children older than 1 year and 0.45 for infants.)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7cdc8a49-e3d5-4c27-83de-a010c63684e0"></a><a name="section-10.4"></a><p></p>
<h2>Administration</h2>
<p class="First">Fluconazole for oral suspension can be taken with or without food.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_432c29d5-444b-40b7-98d9-2638f45239ee"></a><a name="section-10.5"></a><p></p>
<h2>Directions for Mixing the Oral Suspension</h2>
<p class="First">Prepare a suspension at time of dispensing as follows: tap bottle until all the powder flows freely. To reconstitute the <span class="Bold">350 mg bottle, add <span class="Underline">26 mL</span></span> of distilled water or Purified Water (USP) to the bottle and shake vigorously to suspend powder. Each bottle will deliver 35 mL of suspension. To reconstitute the <span class="Bold">1400 mg bottle, add <span class="Underline">24 mL</span></span> of distilled water or Purified Water (USP) to the bottle and shake vigorously to suspend powder. Each bottle will deliver 35 mL of suspension. The concentrations of the reconstituted suspensions are as follows:</p>
<a name="id_93f92935-e196-40fb-83f6-413f9ad06bd1"></a><table border="single" width="443.000">
<col width="49.7%">
<col width="50.3%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><span class="Bold"><span class="Underline">Fluconazole USP Content per Bottle</span></span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold"><span class="Underline">Concentration of Reconstituted Suspension</span></span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle"> 350 mg </td>
<td class="Botrule Rrule" align="center" valign="middle"> 10 mg/mL </td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" valign="middle"> 1400 mg </td>
<td class="Botrule Rrule" align="center" valign="middle"> 40 mg/mL </td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_88949794-2189-4041-a654-63492e9f11f6"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Fluconazole for Oral Suspension is available as a white to off-white, orange-flavored, uniform powder with no agglomeration, which when reconstituted as directed, contains <span class="Bold">10 mg per mL (350 mg per bottle) or 40 mg per mL (1400 mg per bottle)</span>, in a 35 mL bottle. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_87057702-454e-4970-b1d3-c38557921a0c"></a><a name="section-11.1"></a><p></p>
<h2>Storage</h2>
<p class="First">Store dry powder at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. Store reconstituted suspension between 25°C (77°F) and 2°C (36°F) and discard unused portion after 2 weeks. Protect from freezing.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3e767270-e261-4ea3-8634-2628070f190a"></a><a name="section-12"></a><p></p>
<h1>REFERENCES</h1>
<p class="First">1. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard-Third Edition. CLSI Document M27-A3, (ISBN 1-56238-666-2), CLSI, 940 West Valley Road, Suite 1400, Wayne, PA, 19087-1898 USA, 2008. </p>
<p>2. Clinical and Laboratory Standards Institute. Methods for Antifungal Disk Diffusion Susceptibility Testing of Yeasts; Approved Guideline-Second Edition. CLSI Document M44-A2, (ISBN 1-56238-703-0), CLSI, 940 West Valley Road, Suite 1400, Wayne, PA, 19087-1898 USA, 2009. </p>
<p>3. Pfaller, M. A., Messer, S. A., Boyken, L., Rice, C., Tendolkar, S., Hollis, R. J., and Diekemal, D. J. Use of Fluconazole as a Surrogate Marker To Predict Susceptibility and Resistance to Voriconazole Among 13,338 Clinical Isolates of <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> spp</span>. Tested by Clinical and Laboratory Standard Institute-Recommended Broth Microdilution Methods. 2007. Journal of Clinical Microbiology. 45:70–75.</p>
<p>Rev. B 11/2011</p>
<p>Manufactured in India By:</p>
<p><span class="Bold">CIPLA LTD.</span></p>
<p>Goa, India</p>
<p>Manufactured For:</p>
<p><span class="Bold">TEVA PHARMACEUTICALS USA</span></p>
<p>Sellersville, PA 18960</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_3d577724-51f3-45e7-8b58-fa53fe5b9ea2"></a><a name="section-13"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<div class="Figure"><img alt="Fluconazole for Oral Suspension 10mg/mL Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=29bd0efa-fb16-4e69-bb96-8f6bcf80b9f7&amp;name=54a6695b-4502-4454-b56e-653ecd0f3233-02.jpg"></div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_65e6ba3a-c516-4ebe-9711-5f502de6c8a6"></a><a name="section-13.1"></a><p></p>
<h2>Fluconazole for Oral Suspension 10mg/mL Label Text</h2>
<p class="First">NDC 0093-5414-95</p>
<p>FLUCONAZOLE</p>
<p>for Oral Suspension</p>
<p>10 mg/mL</p>
<p>when reconstituted</p>
<p>Each bottle contains 350 mg fluconazole in</p>
<p>a natural orange-flavored mixture. When</p>
<p>reconstituted as directed, each teaspoonful</p>
<p>(5 mL) contains 50 mg of fluconazole.</p>
<p>ORANGE FLAVORED Rx only</p>
<p>35 mL (when reconstituted)</p>
<p>TEVA</p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_0a592d3f-6217-4388-b457-52c214d917d0"></a><a name="section-14"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<div class="Figure"><img alt="Fluconazole for Oral Suspension 40 mg/mL Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=29bd0efa-fb16-4e69-bb96-8f6bcf80b9f7&amp;name=54a6695b-4502-4454-b56e-653ecd0f3233-03.jpg"></div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_84e3d3d1-856d-463c-998e-55e45fb9de45"></a><a name="section-14.1"></a><p></p>
<h2>Fluconazole for Oral Suspension 40mg/mL Label Text</h2>
<p class="First">NDC 0093-5415-95</p>
<p>FLUCONAZOLE</p>
<p>for Oral Suspension</p>
<p>40 mg/mL</p>
<p>when reconstituted</p>
<p>Each bottle contains 1400 mg fluconazole in</p>
<p>a natural orange-flavored mixture. When</p>
<p>reconstituted as directed, each teaspoonful</p>
<p>(5 mL) contains 200 mg of fluconazole.</p>
<p>ORANGE FLAVORED Rx only</p>
<p>35 mL (when reconstituted)</p>
<p>TEVA</p>
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>FLUCONAZOLE 		
					</strong><br><span class="contentTableReg">fluconazole powder, for suspension</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0093-5414</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>FLUCONAZOLE</strong> (FLUCONAZOLE) </td>
<td class="formItem">FLUCONAZOLE</td>
<td class="formItem">10 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MALTODEXTRIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM BENZOATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SUCROSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>XANTHAN GUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ANHYDROUS CITRIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>.ALPHA.-TOCOPHEROL, DL-</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM CITRATE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (white to off-white) </td>
<td class="formLabel">Score</td>
<td class="formItem">    </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0093-5414-95</td>
<td class="formItem">35 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA077523</td>
<td class="formItem">09/22/2008</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>FLUCONAZOLE 		
					</strong><br><span class="contentTableReg">fluconazole powder, for suspension</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0093-5415</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>FLUCONAZOLE</strong> (FLUCONAZOLE) </td>
<td class="formItem">FLUCONAZOLE</td>
<td class="formItem">40 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MALTODEXTRIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM BENZOATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SUCROSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>XANTHAN GUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM CITRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ANHYDROUS CITRIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>.ALPHA.-TOCOPHEROL, DL-</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (white to off-white) </td>
<td class="formLabel">Score</td>
<td class="formItem">    </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0093-5415-95</td>
<td class="formItem">35 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA077523</td>
<td class="formItem">09/22/2008</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Teva Pharmaceuticals USA Inc
							(118234421)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 7/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>54a6695b-4502-4454-b56e-653ecd0f3233</div>
<div>Set id: 29bd0efa-fb16-4e69-bb96-8f6bcf80b9f7</div>
<div>Version: 6</div>
<div>Effective Time: 20120719</div>
</div>
</div> <div class="DistributorName">Teva Pharmaceuticals USA Inc</div></p>
</body></html>
